Introduction
============

The study of cancer biomarker proteins began in 1847 with the discovery by Henry Bence-Jones of what turned out, more than 100 years later, to be a tumor-produced free antibody light chain "Bence Jones protein" in the urine of a multiple myeloma patient ([@b32-bmi-2006-001]; [@b181-bmi-2006-001]) where it was present in large quantities and could be revealed by simple heat denaturation. One hundred and 40 years later this protein was demonstrated to be present also in the serum ([@b306-bmi-2006-001]), and in 1998 a routine immunodiagnostic test was approved by the FDA. Hormones produced by tumors were also detected early on ([@b49-bmi-2006-001]): adrenocorticotropic hormone (ACTH), calcitonin, and chorionic gonadotropin (hCG), for example, are elevated in specific cancer types, though not with the tumor specificity of Bence-Jones proteins.

Unfortunately, the paradigm in which an overproduced tumor-specific protein can be easily detected as a marker of cancer has turned out to be the exception rather than the rule: in the nearly 160 years since Bence-Jones' discovery, less than 10 proteins have progressed to the level of FDA-approved cancer diagnostic tests, and most of these lack ideal sensitivity and specificity for cancer.

In recent years "... the emerging science of genomics and proteomics have generated a plethora of candidate cancer biomarkers" ([@b260-bmi-2006-001]). Unfortunately few of these markers immediately stand out as superior prognostic or diagnostic tools, and even fewer have been validated and approved. Several factors might account for the slow pace of advance in cancer biomarkers. On the one hand, available proteomics technology has limited power to detect low-abundance cancer biomarkers against the background of high-abundance plasma proteins, and many of the best markers may thus be missed until discovery technology improves. On the other hand, the capacity to verify and validate existing candidate markers (through rigorous testing in large sample sets from many diseases) is limited, and it is therefore possible that the required biomarkers have already been "discovered" but not yet validated. In this paper, we are concerned with the latter possibility, and specifically with the problem of selecting among the existing candidates those that are most promising for systematic validation.

This line of enquiry immediately raises the question: where is the list of known candidate cancer biomarkers? While a number of useful reviews and books discuss specific cancer markers with clinical promise, these generally concentrate on proven, or at least well-developed, markers or specific disease states. We were unable to find a list that draws together a large population of candidates at all stages of development from multiple discovery sources, and thus our first step has been to create one through a combination of literature search and other methods.

The value of a list of existing candidates could be limited by the general lack of sensitivity and specificity exhibited by most of the cancer markers found to date, a factor that may have discouraged others from undertaking this task previously. Most candidates that have been followed up in larger studies have shown poor diagnostic value ([Table 1](#t1-bmi-2006-001){ref-type="table"}), and even those that have been approved for clinical use exhibit lower sensitivity and specificity than the well-known markers of, eg, acute cardiovascular events (ie, troponin in myocardial infarction or B-type natriuretic peptide in congestive heart failure, [Table 1](#t1-bmi-2006-001){ref-type="table"}).

On the other hand, there seems to be a growing consensus that panels of markers may be able to supply the specificity and sensitivity that individual markers lack. For example a panel combining four known biomarkers (leptin, prolactin, osteopontin, insulin-like growth factor II), none of which used alone could distinguish patients from the controls, achieved a sensitivity and specificity of 95% for the diagnosis of ovarian cancer ([@b233-bmi-2006-001]). In this case a combination of known proteins in a novel panel provided a significant advance. Xiao et al. identified 299 proteins in tissue culture by 1-D page and nano-ESI-MS/MS but then used ELISA to test 13 of the most interesting in serum. They reported that CD98, fascin, the secreted chain of the polymeric immunoglobulin receptor and 14-3-3 eta provide greater sensitivity when used together as a panel than any of the markers used alone ([@b365-bmi-2006-001]).

If, as we and others ([@b62-bmi-2006-001]) believe, panels of proteins provide the most promising avenue towards early and accurate cancer detection, then a re-examination of known candidates provides a logical approach to panel generation, with the expectation that a stream of new markers can be added as they are identified by marker discovery studies. This candidate-based, or targeted, approach will require a comprehensive list of prioritized candidates coupled with a technology able to assay these in large sets of plasma and serum samples from clinical and epidemiological studies (together a "biomarker pipeline" ([@b16-bmi-2006-001])).

Here we have begun to compile and prioritize a database of candidate biomarkers reported to be differentially expressed in studies of human cancer. We have included changes observed either at the protein (plasma or tissue) or nucleic acid (tissue DNA or RNA) level for any cancer, and excluded results restricted to animal, cell culture systems, or single case report studies in hopes of focusing on the most promising clinical biomarker candidates. We hypothesize that the protein version of most, if not all of these markers should be detectable in blood plasma at some level, irrespective of the tissue source, ultimately allowing for their use in patient screening, diagnosis or follow-up.

Experimental Procedures
=======================

Search strategy
---------------

The principal strategy for creation of our list involved compilation of designated cancer related proteins from: our previously published work ([@b17-bmi-2006-001]), PubMed literature searches, cancer microarrays (868 proteins from 111 human cancer Superarrays (<http://www.superarry.com> and in supplemental material), Circulating Tumor Markers of the New Millennium ([@b364-bmi-2006-001]), American Association for Clinical Chemistry abstracts and general literature perusal. PubMed searches included de novo PubMed literature searches: \[plasma (Title/Abstract) NOT membrane (Title/Abstract) NOT stimulation (Title/Abstract) NOT drug (Title/Abstract) NOT dose (Title/Abstract) AND protein (Title/Abstract) AND cancer\] and \["cancer antigen" AND human\], as well as the PubMed literature search used for proteins from other sources \["protein name" AND cancer AND human AND (where necessary) diagnostic AND (where necessary) expression\] and PubMed "related article" searches. Only proteins for which we found at least one published study on human cancer utilizing primary samples were retained (639 of the array proteins). Each biomarker reference was then manually tabulated and curated as to disease and tissue (including plasma). Single case studies were excluded.

Clinical use data
-----------------

FDA approval dates for tests were obtained from the FDA Center for Devices and Radiological Health database. Proteins designated here as clinical markers are those offered commercially by ARUP or by Mayo Medical Laboratories, or else offered for internal use by either NIH or the Fred Hutchinson Cancer Research Center.

Citation analysis
-----------------

Each documented protein on the resulting list was searched against the literature (via PubMed) using the query \["protein name" AND human AND cancer AND diagnostic\]. This is admittedly a crude metric of research interest in a biomarker, but provides a useful method of relative prioritization among markers. In tabulating citation frequencies we did not exclude those categories ruled out in compiling the list initially: studies of animal systems, single clinical cases, or cell lines. If the "protein name" was not found by this search strategy it was counted as zero. It must be noted that PubMed is not a static archive but rather constantly changing both by additions, subtractions, and redefinition of MeSH headings. Still this exercise allowed some relative ranking of interest and therefore importance. Total cancer citations per year were determined using the query \[human AND cancer AND diagnostic\] limited to a specific publication year.

Annotation
----------

Swiss-Prot/Uniprot accession numbers were obtained where possible. Most of the TrEMBL annotations were done prior to the addition of species information to the annotation number and so this form of the annotation was maintained. Candidate cancer biomarkers were annotated with GO numbers and IDs from EBI's human GOA 30.0 (gene_association.goa_human, <ftp://ftp.ebi.ac.uk/pub/databases>) and the Gene Ontology's GO.def version 1.213 (<http://www.geneontology.org/ontology/GO.defs>) respectively. Similar ID groupings were then combined. The entire Human GO file was treated in an identical fashion for comparison with the candidates.

Protein concentrations
----------------------

Where possible, normal or control values for the plasma concentration of each protein were obtained by literature search. Unless specifically noted, protein concentrations are for the intact protein not individual subunits.

Results
=======

A search strategy combining literature search, extraction from microarray data, and a review of existing clinical tests, followed by manual curation, provided a list of 1261 candidate protein biomarkers (supplemental material) for which we found evidence of a quantitative change in some human cancer. As shown in [Table 2](#t2-bmi-2006-001){ref-type="table"}, the candidates included proteins known to occur in plasma (274), proteins detected in tissue samples (542), and proteins whose corresponding mRNA or DNA levels were differentially expressed between cancerous and normal samples (656). These categories are non-exclusive in that a significant number of the candidates were found in more than one type of study. Proteins detected in the plasma represent 22% of the total proteins documented to date.

Citation frequency
------------------

Citation frequency analysis was used as one method of prioritizing the biomarkers, on the assumption that proteins most widely studied in the context of cancer had more promise as biomarkers. Citation frequency was determined using a PubMed query intended to count citations in which the authors considered the proteins to have diagnostic value ([Figure 1](#f1-bmi-2006-001){ref-type="fig"}, [Table 3](#t3-bmi-2006-001){ref-type="table"}). When this is done, 29% of the 1,261 biomarkers have no such citations, 67% have fewer than 10, and 74% fewer than 20. Likewise only a very limited number of biomarkers have extensive citations, 62 proteins or only 5% of the total number of biomarkers were found to have greater than 500 citations.

Biomarkers with greater than 500 citations
------------------------------------------

Of the 34 biomarkers with more than 1000 citations ([Figure 2](#f2-bmi-2006-001){ref-type="fig"}, [Table 3](#t3-bmi-2006-001){ref-type="table"}) 79% are found in the plasma and 56% are presently used clinically (89% of which are reported in plasma). Of the 28 markers with between 500 and 1000 citations ([Figure 3](#f3-bmi-2006-001){ref-type="fig"}) 57% are plasma proteins but only 7% are used clinically. Both of the markers used clinically are plasma proteins. Some proteins with high citation frequency (eg, albumin) are somewhat surprising to see in the context of cancer biomarkers; these have been retained nevertheless because they appear to have reasonable relevance (low serum albumin levels are prognostic of poor survival ([@b198-bmi-2006-001]) as noted in the table contents).

Proteins with a large number or percentage of citations in 2004
---------------------------------------------------------------

In an effort to include more recently discovered biomarkers we also looked at the proteins that had greater than 100 citations in 2004 or greater than 50% of their citations in 2004. Of the proteins with more than 100 citations in 2004, all but COX2 are represented in [figures 2](#f2-bmi-2006-001){ref-type="fig"} and [3](#f3-bmi-2006-001){ref-type="fig"}. Of those with a majority of total citations occurring in 2004, most have a low number (\<10) of absolute citations ([Figure 4](#f4-bmi-2006-001){ref-type="fig"}, [Table 3](#t3-bmi-2006-001){ref-type="table"}), 32% are detected in plasma and none are presently being used clinically.

Time evolution of biomarker citations
-------------------------------------

We tracked the number of citations per year for selected cancer biomarkers over the last 35 years ([Figure 5](#f5-bmi-2006-001){ref-type="fig"}). The number of times a protein was cited in a given year ("protein name" AND cancer AND human AND diagnostic) was divided by the total number of cancer citations for that year (cancer AND human AND diagnostic) to give a rough index of the prominence of the biomarker in cancer research. Although frequently cited in the 1970's and 1980's, interest in CEA has dropped dramatically. The most cited marker in this group, PSA, has well-documented limitations as a diagnostic yet it continues to be cited either as the only option or as the biomarker upon which to improve. Interest in most of these biomarkers evolves in a fairly similar way: each appears to take a few years to be recognized, followed by gradually increasing interest over the following 15 to 20 years. Of these markers the FDA has approved only three as diagnostic cancer antigens: alpha-fetoprotein, CEA, and PSA (approved May 31, 1988, October 15, 1980 and February 25, 1986 respectively; [Figure 5](#f5-bmi-2006-001){ref-type="fig"}). To date only 6 additional markers have been approved by the FDA under the category of tumor associated antigens: CA 19-9 in May of 2002, Her2/Neu in September of 2000, CA 15.3 in February of 1981, bladder tumor marker in April of 1997, thyroglobulin in March of 1999 and CA 125 in July of 1987 (Table 4). None of these markers, used singly, has over 90% sensitivity and specificity. Although these numbers are for specific assays, they are representative of the general lack of specificity and sensitivity of the individual cancer markers currently available.

Concentration range of cancer plasma biomarkers
-----------------------------------------------

We attempted to collect normal plasma concentrations for candidate cancer biomarkers reported in the literature. The resulting 211 values were histogramed ([Figure 6](#f6-bmi-2006-001){ref-type="fig"}) for comparison with the distributions of concentrations of either unselected plasma proteins from PPI's plasma protein database, or a set of candidate cardiovascular biomarkers ([@b15-bmi-2006-001]). The cancer candidates cover a \>10-log concentration range with proteins such as immune modulating interleukins (1α andβ, 2, 5, 6, 9, 10, IFN-γ and GM-CSF) being present in normal plasma or serum in the pg/mL range while classical plasma proteins (albumin, transferrin, fibrinogen, and α-2-macroglobulin) are present at mg/mL levels. When the cancer candidate distribution is compared to the concentrations for all plasma proteins (unpublished results) and plasma markers of cardiac disease, a greater proportion of the cancer candidates appear in the lower concentration ranges than general plasma proteins or cardiac markers. Thus normal values for 185 (88%) of the markers for which we know the plasma concentration fall below 10 microgram/mL and 103 (49%) fall below 10 ng/mL. Tabulated concentrations are those found in controls not patients. Thus in many cases these may increase in cancer, thereby aiding in their detection.

Genome Ontology classification of cancer candidate biomarkers
-------------------------------------------------------------

We compared the distribution of GO annotations for the cancer candidates with the distribution for all annotated human proteins over a series of summary categories, with the aim of finding any large biases in the cancer group. In comparing "Biological Process" GO annotation, the cancer biomarkers show an increased representation of apoptosis, cell cycle and proliferation annotations; processes blocked or increased in tumors ([Figure 7](#f7-bmi-2006-001){ref-type="fig"}); while metabolism, catabolism and transport proteins are decreased. When the two sets are compared by "Cellular Component" GO terms ([Figure 8](#f8-bmi-2006-001){ref-type="fig"}), the extracellular category is over represented in the cancer biomarker database in comparison with the whole human database (20% versus 6% respectively). This is true even if the proteins found experimentally in plasma are excluded (12% extracellular). The other Cellular Component categories show only small differences between the proteins sets. Comparing "Molecular Function" GO terms, only small differences are apparent between the cancer candidates and the whole annotated human proteome.

Prioritization of candidates
----------------------------

Given the size of the list of candidates resulting from our assembly procedure, we attempted to select a smaller subset of higher priority candidates as a starting point for consideration of assay development and clinical validation. This subset comprising 260 proteins ([Table 3](#t3-bmi-2006-001){ref-type="table"}) was compiled from the most highly cited proteins, the "recent" markers, plasma proteins of known concentration (indicating existence of an assay) and any marker presently in any type of clinical use. Many of these markers fall into expected categories such as immune modulation molecules (acute phase proteins, coagulation factors, immune modulators); and mediators of classical cancer pathways (oncoproteins, angiogenic or apoptosis factors, tumor suppressors or antigens, cellular homing or proliferation molecules). Somewhat less expected perhaps is that almost 22 (8%) of these top 262 proteins are involved in hormonal action.

Existence of a specific antibody
--------------------------------

For each of the 260 high priority candidates, we performed web searches, primarily through the Exact Antigen website ([www.exactantigen.com](www.exactantigen.com)), to determine whether an antibody with potential utility in a plasma assay is commercially available. Relevant antibodies were found for 186 (72%) of the 260 high priority candidates.

Discussion
==========

According to the Centers for Disease Control, 1 in every 4 deaths in the United States is due to cancer. Many of these deaths could be averted by improved early cancer detection, since existing therapies, especially surgery, are much more effective in early cancer stages as compared to later stages ([@b87-bmi-2006-001]). Billions of dollars have been spent on basic research looking for molecular differences related to cancer-work that has been at least partly motivated by the need for improved in vitro diagnostic tests to detect or monitor progression of cancer. Yet to our knowledge no centralized database of known candidate cancer biomarkers exists. Such a list could serve to confirm new results, eg, from proteomic comparisons of cancer and control sera, by placing them in a context of earlier work. Additionally it could serve as a reservoir of current and future candidates to be tested in large sample sets by candidate-based ("targeted" or "directed") proteomics methods. The latter use is important, since candidate-based methods, consisting of specific assays for defined targets, are likely to be much more sensitive than proteome profiling methods, and hence could cover a much broader universe of protein candidates and potentially detect disease states earlier.

The present catalog of 1261 human candidate cancer biomarkers is a first attempt at such a database. We did not select specific cancer types or specific detection methods, choosing instead to cast a broad net. In the resulting list, it will be apparent that the strength of evidence and likelihood of ultimate usefulness of the candidates varies widely. Even candidates that have been tested and found to have poor diagnostic specificity and sensitivity were retained, as they may nevertheless contribute to useful panels as in the work of Mor and Xiao. Looking at the list, one might question why the most abundant plasma protein (serum albumin) is included -- though perhaps counter-intuitive, albumin does meet the search criteria used, and is in fact a useful negative acute phase indicator likely to be altered in cancer along with many inflammation-related proteins. Other well-known proteins not usually considered as cancer-specific are also included (eg, protein and peptide hormones overproduced by endocrine tumors or through ectopic synthesis). Overall, the list is not easily recognizable by inspection as a list of cancer markers.

Of the 1261 proteins, 22% are reported to occur in plasma. This is an appreciable fraction considering that many of the large array studies, capable of finding many markers per experiment, have looked for differential protein or DNA expression in tissues. For bona fide cell-associated cancer markers such as Her-2, there is persuasive evidence that at least a fragment of the protein molecule is released into the plasma and can be detected as a cancer biomarker ([@b343-bmi-2006-001]), and other proteins documented here in the tissues of cancer patients have been demonstrated to be found in plasma in other disease indications. These cases provide some support for the hypothesis that most if not all of the 1261 proteins should be detectable at some level in plasma, the diagnostic sample of choice, given a sensitive enough assay. Whether current assay technologies will be sensitive enough to see a large fraction of the candidates in plasma is a major question at this point, and one that will require vigorous efforts to resolve.

As might be expected, there is a smooth distribution in the number of literature citations per candidate, ranging from almost 8,000 (for PSA) to zero (for candidates not mentioned as diagnostic by the publication's authors). This result suggests that our literature analysis did not identify a crisply defined set of cancer markers, but rather part of a continuum extending from a few established markers through plausible candidates into more speculative possibilities. Given the complexity of cancer, such an outcome is not surprising.

Only 5% of the 1261 candidates have been extensively studied (500 or greater total citations over the years). When examined as a function of time, the citation history of individual markers appears to show a slow evolution of interest that peaks 15 to 20 years after the initial papers. Only in the cases of CEA and PSA was discovery of a biomarker followed by a rapid increase in publications over a few years and in the case of PSA the steady increase was seen only 10 years after the first citations appeared. Thus in order to catch recently emerged candidates, we focused on candidates with a high proportion of citations occurring in 2004 but with fewer total citations (often 10 or less). Of the total 1261 proteins only 41 are used in some clinical sense and even fewer have FDA approved assays.

While the observed slow pace is easily explained by the deliberate nature of clinical research and the progressive, rather than abrupt, nature of adoption in medical practice, it presents a stark reminder of the challenge involved in making any rapid advance in cancer diagnostics.

These candidate cancer markers, taken as a group, appear to be present in plasma at lower concentrations than comparable groups of cardiac markers or unselected plasma proteins. Although systematic biases in selection of these groups could affect this result, it tends to support the contention that plasma cancer marker discovery is, and may continue to be, a challenge in terms of detection sensitivity. Present discovery proteomics platforms typically detect proteins with plasma concentrations in the mg/mL to microg/mL range. For the proteins in our list with known plasma concentrations, we estimate that 86% would be missed by most conventional proteomics platforms, while 48% would be missed by high-end proteomics platforms with extensive multi-dimensional fractionation. For the present, the only way that many of these proteins can be detected is by specific assays: ie, by targeted proteomics. Targeted proteomics thus represents a preferred path to validation and further study of the candidate markers listed here.

The distribution of our cancer biomarker candidate proteins among GO annotation categories shows remarkable similarity to the distribution for all annotated human proteins. There is some enrichment for proteins annotated as related to apoptosis, cell cycle and proliferation (in the GO biological process category), as would be expected on account of the fundamental involvement of these processes in cancer. The extracellular group (in the GO cell component category) is also somewhat over-represented, a trend favorable to detection in plasma. Nevertheless the candidates seem to represent a very wide sampling of the human proteome.

The full set of these 1,261 candidates is too large to submit for immediate verification and validation in large sample sets by any available means, and some method of prioritization is required to initiate their evaluation. As an initial approach, we have selected a subset of the candidates based on a set of criteria including number of total citations, number of recent citations, proportion of recent citations, known plasma concentration (implying existence of an assay) and clinical use in any context. This subset of 260 candidates (presented in [Table 3](#t3-bmi-2006-001){ref-type="table"}) includes 186 candidates for which a relevant antibody is commercially available, opening the possibility of testing this group using an antibody array or other miniaturized immunoassay technology in the near future.

While the list of candidate cancer biomarkers assembled here is clearly a simplistic and therefore somewhat crude initial catalog, we believe the result will prove to be of sufficient value to justify extending the effort to provide an ongoing summary of the progress of cancer diagnostics. In particular we believe that linking a database of marker candidates to the bioinformatics architecture used in biomarker discovery will help to connect the discovery and validation phases ([@b16-bmi-2006-001]) necessary for progression of biomarkers to the clinic. One can envision a steady accumulation of candidates, regular revision of candidate priorities as evidence emerges from multiple sources (literature, microarrays, systems models, etc), and finally feedback in the form of specific measurements from validation studies in large sample sets. Such a collection of data would provide an up-to-date snapshot of the workings of a cancer diagnostic marker pipeline.

Finally, lists such as this prompt important, but infrequently-asked questions regarding the most productive tack for future discovery efforts. Is it reassuring to find confirmation of fresh observations through overlap with a pre-existing list? Perhaps so, and particularly if the candidates involved appear repeatedly in similar independent studies. However the sieve used here is crude and so our list cannot really "confirm" a candidate seen in a new study--overlap just improves the odds of relevance. Further, since there are certain to be good cancer markers not on this list, failure to appear here in no way disqualifies a novel marker. Hence our hope is to contribute a mechanism for marginally improving chances of recognizing a valid marker, and a systematic source for enriched candidates available for validation and panel assembly efforts.
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![Biomarker Citation Frequency. Citation Frequency for each protein was determined using the PubMed query \["protein name" AND human AND cancer AND diagnostic\]. Proteins were then histogrammed in bins of 10, 100 and 1000 citations (for frequencies of n\<100, 100\<n\<1000, and n\>1000, respectively) and each bin's count normalized through division by bin size (eg the count of proteins falling in the 11--20 citations bin was divided by 10).](bmi-2006-001f1){#f1-bmi-2006-001}

![Proteins with greater than 1000 citations in [Fig 1](#f1-bmi-2006-001){ref-type="fig"}. White bars indicate non plasma proteins not used clinically, light gray bars indicate clinically used proteins not yet detected in plasma, dark gray bars indicate plasma proteins not used clinically and black bars indicate plasma proteins used clinically. CEA = Carcinoembryonic Antigen, PSA = Prostate Specific Antigen, ER alpha = Estrogen Receptor alpha, LH = Luteinizing Hormone, PR = Progesterone Receptor, PCNA = Proliferating Cell Nuclear Antigen, FSH = Follicle-stimulating Hormone, NSE = Neuron-specific enolase, PH=Parathyroid Hormone.](bmi-2006-001f2){#f2-bmi-2006-001}

![Proteins with greater than 500 but less than 1000 citations in [Fig. 1](#f1-bmi-2006-001){ref-type="fig"}. White bars indicate non-plasma proteins not used clinically, dark gray bars indicate plasma proteins not used clinically and black bars indicate plasma proteins used clinically. Beta-2-MG = Beta--2-microglobulin, IFN-gamma = IFN-gamma, CRP = C reactive protein, CGA = Chromogranin A, EPN = Erythropoietin, VWF=Von Willebrand Factor.](bmi-2006-001f3){#f3-bmi-2006-001}

![Proteins of "recent" interest (more than 50% of [Fig. 1](#f1-bmi-2006-001){ref-type="fig"}., citations occurring in 2004). White bars indicate non-plasma proteins not used clinically, dark gray bars indicate plasma proteins not used clinically. MG B = Mammaglobin B, HG = Haptoglobin 1, S-gamma = Synuclein-gamma, NESP-55 = Neuroendocrine secretory protein-55, CDK-6 = Cyclin-dependent kinase 6, 17betaHD1 = 17 beta-Hydroxys-teroid dehydrogenase type 1.](bmi-2006-001f4){#f4-bmi-2006-001}

![Evolution of Marker Interest. The number of times a marker is cited in a particular year divided by the total number of cancer citations for that year. Solid gray stars designate when the FDA approved CEA, PSA and alpha-fetoprotein. CEA = Carcinoembryonic Antigen, PSA = Prostate Specific Antigen, PDGRFR = Platelet-derived Growth Factor Receptor alpha.](bmi-2006-001f5){#f5-bmi-2006-001}

![Distribution of Normal Plasma Concentrations for Plasma Cancer Biomarkers. The number of plasma concentrations falling within a given log of pg/ml were normalized to percent of total and then were histogrammed in log bins. The concentrations of the 211 cancer biomarkers detected in plasma are represented by the solid line, the concentrations of the unselected plasma proteins by the dashed line, and the concentration of cardiac biomarkers by the dotted line.](bmi-2006-001f6){#f6-bmi-2006-001}

![Distribution by Biological Process. Genome Ontology categories for A) Cancer biomarker proteins, B) Overall human proteome (genome data).](bmi-2006-001f7){#f7-bmi-2006-001}

![Distribution by Cellular Component. Genome Ontology categories for A) Cancer biomarker proteins, B) Overall human proteome (genome data).](bmi-2006-001f8){#f8-bmi-2006-001}

![Distribution by Molecular function. Genome Ontology categories for A) Cancer biomarker proteins, B) Overall human proteome (genome data).](bmi-2006-001f9){#f9-bmi-2006-001}

###### 

Example sensitivities and specificities for the nine FDA approved cancer biomarkers.

  Marker                                                                            Disease                           Cut Off                                                 Sensitivity   Specificity                                       Reference
  --------------------------------------------------------------------------------- --------------------------------- ------------------------------------------------------- ------------- ------------------------------------------------- ------------------------
  CEA                                                                               malignant pleural effusion        NA[1](#tfn1-bmi-2006-001){ref-type="table-fn"}          57.5%         78.6%                                             ([@b194-bmi-2006-001])
  CEA                                                                               peritoneal cancer dissemination   0.5 ng/ml                                               75.8%         90.8%                                             (Yamamto et al. 2004)
  Her-2/neu                                                                         stage IV breast cancer            15 ng/mL                                                40%           98%[2](#tfn2-bmi-2006-001){ref-type="table-fn"}   ([@b63-bmi-2006-001])
  Bladder Tumor Antigen                                                             urothelial cell carcinoma         NA                                                      52.8%         70%                                               ([@b224-bmi-2006-001])
  Thyroglobulin                                                                     thyroid cancer metastasis         2.3 ng/ml[3](#tfn3-bmi-2006-001){ref-type="table-fn"}   74.5%         95%                                               ([@b197-bmi-2006-001])
  Alpha-fetoprotein                                                                 hepatocellular carcinoma          20 ng/ml                                                50%           70%                                               ([@b70-bmi-2006-001])
  PSA                                                                               prostate cancer                   4.0 ng/mL                                               46%           91%                                               ([@b95-bmi-2006-001])
  CA 125                                                                            non-small cell lung cancer        95 IU/mL                                                84%           80%                                               ([@b65-bmi-2006-001])
  CA19.9                                                                            pancreatic cancer                 NA                                                      75%           80%                                               ([@b369-bmi-2006-001])
  CA 15.3                                                                           breast cancer                     40 U/ml                                                 58.2%         96.0%                                             ([@b57-bmi-2006-001])
  leptin, prolactin, osteopontin, and IGF-II                                        ovarian cancer                    NA                                                      95%           95%                                               ([@b233-bmi-2006-001])
  CD98, fascin, sPIgR[4](#tfn4-bmi-2006-001){ref-type="table-fn"}, and 14-3-3 eta   lung cancer                       NA                                                      96%           77%                                               ([@b365-bmi-2006-001])
  Troponin I                                                                        myocardial infarction             0.1 microg/L                                            93%           81%                                               ([@b83-bmi-2006-001])
  B-type natriuretic peptide                                                        Congestive heart failure          8 pg/mL                                                 98%           92%                                               ([@b67-bmi-2006-001])

Not available

vs benign breast diseases

vs 3rd week post surgery

Secreted chain of the polymeric immunoglobulin receptor

###### 

Distribution of cancer biomarkers. Other = amniotic, bile, cerebrospinal fluid, follicular fluid, milk of lactating women, pancreatic fluid, seminal plasma, sputum, stools and urine.

  1261 Unique proteins   Proteins in plasma   Tissue proteins   DNA & RNA data   Other
  ---------------------- -------------------- ----------------- ---------------- -------
  Proteins in plasma     274                  60                24               6
  Tissue proteins        60                   542               152              6
  DNA & RNA data         24                   152               656              3
  Other                  6                    6                 3                15

###### 

High priority cancer markers. Proteins having \> 500 total citations, \>100 citations in 2004, \>50% 2004 citations, a known plasma concentration or used clinically are listed.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein Names                                                                       Citations   Plasma Conc Known in pg/ml   Clinical Markers   Total \# of ✓ s   Available Antibody   Human Swiss Prot \#   Control Plasma conc pg/ml   Concentration Reference   Comments                                                                                              
  ----------------------------------------------------------------------------------- ----------- ---------------------------- ------------------ ----------------- -------------------- --------------------- --------------------------- ------------------------- ---------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alpha-fetoprotein                                                                   ✓           ✓                                               ✓                 ✓                    4                     yes                         P02771                    2.0E+04    ([@b33-bmi-2006-001])                                                                      A pregnancy associated oncofetal protein reexpressed in hepatocellular cancer, cirrhosis and hepatitis ([@b52-bmi-2006-001]).

  Carcinoembryonic antigen                                                            ✓           ✓                                               ✓                 ✓                    4                     yes                         P06731                    1.0E+03    ([@b218-bmi-2006-001]) ([@b86-bmi-2006-001])                                               A reexpressed onco-fetal protein, CEA is currently in use in colorectal cancer diagnosis even though its sensitivity can be particularly low in the initial stages ([@b121-bmi-2006-001]).

  Epidermal growth factor receptor                                                    ✓           ✓                                               ✓                 ✓                    4                     yes                         P00533                    6.9E+06    ([@b28-bmi-2006-001])                                                                      A membrane tyrosine kinase that inhibits apoptosis and promotes angiogenesis. Found to be connected with increased malignancy ([@b143-bmi-2006-001]).

  Kallikrein 3 (prostate specific antigen)                                            ✓           ✓                                               ✓                 ✓                    4                     yes                         P07288                    1.9E+03    ([@b124-bmi-2006-001]) ([@b240-bmi-2006-001])                                              PSA hydrolyzes the high molecular mass seminal vesicle protein thus leading to the liquid fraction of the seminal coagulum It is increased in men with prostate cancer ([@b335-bmi-2006-001]).

  Vascular endothelial growth factor A, VEGF                                          ✓           ✓                                               ✓                 ✓                    4                     yes                         P15692                    2.0E+02    ([@b228-bmi-2006-001])                                                                     VEGF is a potent angiogenic factor. Serum levels have been detected in melanoma ([@b350-bmi-2006-001]), pituitary ([@b166-bmi-2006-001]) and colorectal carcinomas ([@b68-bmi-2006-001]).

  Albumin                                                                             ✓           ✓                                               ✓                                      3                     yes                         P02768                    4.1E+10    ([@b183-bmi-2006-001])                                                                     A serum protein responsible for colloidal osmotic pressure and plasma molecule transport. It is decreased in end stage renal disease([@b157-bmi-2006-001]).

  CA 125                                                                              ✓           ✓                                                                 ✓                    3                     yes                         x                                    ([@b363-bmi-2006-001]) ([@b112-bmi-2006-001])                                              A monoclonal antibody identified cancer antigen that is Elevated in most clinically advanced ovarian carcinomas and which may be elevated prediagnosis CA 125 is a potentially useful for early detection. However, CA 125 is not always elevated in malignant cancer and can be elevated in benign ovarian tumors ([@b220-bmi-2006-001]).

  Calcitonin                                                                          ✓                                                           ✓                 ✓                    3                     yes                         P01258                    1.0E+01    ([@b153-bmi-2006-001])                                                                     A thyroid hormone that lowers calcium and phosphate levels and inhibits bone resorption, calcitonin is useful in the detection of thyroid cancers however it is also elevated in Hashimoto's thyroiditis ([@b153-bmi-2006-001]).

  Chromogranin A (parathyroid secretory protein 1)                                    ✓                                                           ✓                 ✓                    3                     NF                          P10645                    6.5E+04    ([@b261-bmi-2006-001])                                                                     A neuroendocrine secretory protein secreted by tumours with neuroendocrine properties. The assay is used primarily in the diagnosis and monitoring of patients with tumours of neuroendocrine origin. Increased levels in small cell lung cancer patients are associated with shorter survival ([@b261-bmi-2006-001]).

  Corticotropin-lipotropin contains ACTH                                              ✓                                                           ✓                 ✓                    3                     yes                         P01189                    1.1E+01    ([@b357-bmi-2006-001])                                                                     Coritcotropin-lipotropin contains melanotropin which increases pigmentation of the skin and ACTH which stimulates the adrenal glands to secret cortisol. It is secreted by some pituitary tumors ([@b51-bmi-2006-001]). Concentration for ACTH.

  Estrogen receptor 1                                                                 ✓           ✓                                                                 ✓                    3                     yes                         P03372                                                                                                                          The estrogen receptor is a steroid receptor which stimulates hormone-specific transcription of specific genes. Most breast cancers express estrogen and progesterone receptor (ERalpha and PR) ([@b58-bmi-2006-001]).

  Gastrin                                                                             ✓                                                           ✓                 ✓                    3                     yes                         P01350                    6.9E+02    ([@b340-bmi-2006-001])                                                                     A hormone that stimulates HCl secretion by the gastric mucosa, it is increased in gastric and colorectal cancer patients ([@b340-bmi-2006-001]).

  Progesterone receptor                                                               ✓           ✓                                                                 ✓                    3                     yes                         P06401                                                                                                                          The progesterone receptor is a steroid receptor which stimulates hormone-specific transcription of specific genes. There is a loss of expression in prostate cancer tissue ([@b144-bmi-2006-001]).

  Prolactin                                                                           ✓                                                           ✓                 ✓                    3                     yes                         P01236                    1.6E+04    ([@b8-bmi-2006-001])                                                                       A hormone that stimulates and sustains lactation Multiple regression analysis showed a significant correlation between tumor volume and serum PRL level in prolactinoma ([@b205-bmi-2006-001]).

  S100 alpha chain                                                                    ✓           ✓                                               ✓                                      3                     yes                         P23297                    9.0E+01    ([@b329-bmi-2006-001])                                                                     A calcium binding protein, S100 has been described as a useful tumor marker for malignant melanoma ([@b329-bmi-2006-001]). Concentration is for the complex protein.

  Somatostatin                                                                        ✓                                                           ✓                 ✓                    3                     NF                          P61278                    2.0E+01    ([@b239-bmi-2006-001])                                                                     Somatostatin inhibits secretion of growth hormone, insulin, glucagon, gastrin , cholecystokinin, secretin and vasoactive intestinal peptide among others. It has been detected in the sera of 14--15% of lung cancer patients although tumor cell expression appears rare ([@b247-bmi-2006-001]).

  Thyroglobulin                                                                       ✓                                                           ✓                 ✓                    3                     yes                         P01266                    1.0E+03    ([@b232-bmi-2006-001])                                                                     Precursor to the thyroid hormones thyroxine and triiodothyronine its level in plasma is used in the management of thyroid cancer ([@b360-bmi-2006-001]).

  V-erb-b2, Her2/neu                                                                  ✓                                                           ✓                 ✓                    3                     yes                         P04626                    1.1E+04    ([@b364-bmi-2006-001])                                                                     An oncogene product whose tissue expression and levels of the shed protein in serum have been shown to correlate with tumor stage in a range of adenocarcinomas ([@b344-bmi-2006-001]).

  Antigen identified by monoclonal antibody Ki-67                                     ✓           ✓                                                                                      2                     NF                          P46013                                                                                                                          A proliferation-associated antigen that is increased in small cell lung cancer patients ([@b103-bmi-2006-001]).

  B-cell CLL/lymphoma 2                                                               ✓           ✓                                                                                      2                     yes                         P10415                                                                                                                          An inhibitor of apoptosis Bcl-2 maintains homeostasis in the immune system The differing effects of Bcl-2 expression on prognosis may be due to which cells are expressing the Bcl-2, immune cells or tumors. High expression in ovarian cancer ([@b123-bmi-2006-001]) and non small lung cancer ([@b302-bmi-2006-001]) are associated with better prognosis whereas well differentiated tumors more likely to be Bcl-2 positive ([@b310-bmi-2006-001]).

  BCL2-associated X protein                                                           ✓           ✓                                                                                      2                     yes                         Q07812\                                                                                                                         Bax is an apoptosis inhibitor highly expressed in Hodgkin's disease ([@b293-bmi-2006-001]).
                                                                                                                                                                                                                                           Q07814\                                                                                                                         
                                                                                                                                                                                                                                           Q07815                                                                                                                          

  Beta-2-microglobulin                                                                ✓                                                           ✓                                      2                     yes                         P61769                    2.1E+06    ([@b35-bmi-2006-001])                                                                      The nonpolymorphic chain of MHC class I molecules. It is slightly increased in children with acute leukemias and lymphomas but not in solid tumor disorders.

  Breast cancer 1 early onset                                                         ✓           ✓                                                                                      2                     yes                         P38398                                                                                                                          The BRCA1 protein is a tumor suppressor that mediates DNA damage and repair, transcriptional activity and chromosomal stability. However, while inherited mutations of BRCA1 are responsible for about 40--45% of hereditary breast cancers, these mutations account for only 2--3% of all breast cancers ([@b278-bmi-2006-001]).

  CA 15.3                                                                             ✓                                                                             ✓                    2                     yes                         x                                                                                                                               A monoclonal antibody identified cancer antigen increased in patients with metastatic breast cancer ([@b199-bmi-2006-001]).

  CA 19.9                                                                             ✓                                                                             ✓                    2                     NF                          x                                                                                                                               A monoclonal antibody identified cancer antigen increased in colorectal cancer patients ([@b199-bmi-2006-001]).

  Cadherin 1 type 1 E-cadherin (epithelial)                                           ✓                                                           ✓                                      2                     yes                         P12830                    7.0E+06    ([@b48-bmi-2006-001])                                                                      E-cadherin, a cell adhesion protein, plays a role in tissue formation and architecture. Elevated levels of sE-cadherin are found in sera of patients with bladder cancer and correlate with known prognostic factors. ([@b104-bmi-2006-001]).

  Caspase 3                                                                           ✓           ✓                                                                                      2                     yes                         P42574                                                                                                                          Caspase 3 is involved in not only apoptosis execution but also proliferation. It has been shown to be downregulated in gastric lymphoma tissue but negatively associated with lymph node metastases in gastric carcinoma ([@b324-bmi-2006-001]).

  CD44 antigen                                                                        ✓                                                           ✓                                      2                     yes                         P16070                    2.2E+05    ([@b199-bmi-2006-001])                                                                     Certain CD44 isoforms that regulate activation and migration of lymphocytes and macrophages may also enhance local growth and metastatic spread of tumor cells. Present in serum of normal individuals it is elevated in the serum from gastric and colon cancer patients, ([@b107-bmi-2006-001]), Hodgkin's lymphoma patients([@b199-bmi-2006-001]), and acute leukemia patients ([@b375-bmi-2006-001]).

  Cellular tumor antigen p53                                                          ✓           ✓                                                                                      2                     yes                         P04637                                                                                                                          The p53 tumor suppressor protein regulates proliferation, cell cycle checkpoints, and apoptosis. More than one half of all lung cancers contain a mutation of the p53 tumor suppressor gene ([@b147-bmi-2006-001]).

  Coagulation factor II, prothrombin                                                  ✓                                                           ✓                                      2                     yes                         P00734                    1.2E+03    ([@b221-bmi-2006-001]) conc. for thrombin fragment                                         A coagulation factor seen in cancers with deep venous thrombosis ([@b101-bmi-2006-001]).

  Colony stimulating factor 2 (granulocyte-macrophage)                                ✓                                                           ✓                                      2                     yes                         P04141                    1.0E+01    ([@b325-bmi-2006-001])                                                                     A hematopoietic cytokine that promotes the maturation of bone marrow cells into antigen presenting cells. Some metastatic tumors produce GM-CSF ([@b325-bmi-2006-001]).

  Colony stimulating factor 3 (granulocyte)                                           ✓                                                           ✓                                      2                     yes                         P09919                    1.8E+01    ([@b142-bmi-2006-001])                                                                     G-CSF is a hematopoietic cytokine generated at infection sites to recruit and replace neutrophils consumed in an immune reaction. It is produced by some metastatic tumors ([@b325-bmi-2006-001]).

  C-reactive protein                                                                  ✓                                                           ✓                                      2                     yes                         P02741                    2.0E+06    ([@b37-bmi-2006-001])                                                                      An inflammation indicator, increased CRP levels are considered to be an important risk factor for atherosclerosis, myocardial infarction, peripheral vascular disease, and ischemic stroke. It is positively correlated with weight loss, anorexia-cachexia syndrome, extent of disease, and recurrence in advanced cancer. Its role as a predictor of survival has been shown in multiple myeloma, melanoma, lymphoma, ovarian, renal, pancreatic, and gastrointestinal tumors ([@b209-bmi-2006-001]).

  Cyclin D1                                                                           ✓           ✓                                                                                      2                     yes                         P24385                                                                                                                          Cyclins are in all proliferating cell types and collectively control the progression of cells through the cell cycle. Genetic alterations affecting p16(INK4a) and cyclin D1, proteins that govern phosphorylation of the retinoblastoma protein (RB) and control exit from the G1 phase of the cell cycle, are so frequent in human cancers that inactivation of this pathway may well be necessary for tumor development ([@b300-bmi-2006-001]).

  Cyclin-dependent kinase inhibitor 1, p21                                            ✓           ✓                                                                                      2                     yes                         P38936                                                                                                                          P21 is a cyclin-dependent kinase inhibitor that blocks cell cycle progression. It is suppressed in malignant nasopharyngeal epithelial cells([@b93-bmi-2006-001]), but overexpressed in pancreatic ductal adenocarcinoma ([@b122-bmi-2006-001]).

  Erythropoietin                                                                      ✓                                                           ✓                                      2                     yes                         P01588                    1.0E+05    ([@b213-bmi-2006-001])                                                                     A stimulator of erythropoiesis associated with malignant cells and tumor vasculature in breast cancer ([@b2-bmi-2006-001]).

  Fibrinogen alpha/alpha-E chain                                                      ✓                                                           ✓                                      2                     yes                         P02671                    2.7E+09    ([@b37-bmi-2006-001])                                                                      A coagulation factor increased in cancer patients without inflammation ([@b37-bmi-2006-001]).

  Follicle-stimulating hormone                                                        ✓                                                                             ✓                    2                     yes                         P01225                                                                                                                          Follicle-stimulating hormone enables ovarian folliculogenesis to the antral follicle stage and is essential for Sertoli cell proliferation and maintenance of sperm quality in the testis. It is decreased in testicular cancer ([@b208-bmi-2006-001]).

  Gamma enolase                                                                       ✓                                                           ✓                                      2                     yes                         P09104                    1.3E+04    ([@b26-bmi-2006-001])                                                                      Neuron specific enolase, a glycolytic enzyme, is released into the CSF when neural tissue is injured. Neoplasms derived from neural or neuro-endocrine tissue may release NSE into the blood. Elevated levels are found in seminomas ([@b90-bmi-2006-001]), advanced non-small cell lung cancer ([@b26-bmi-2006-001]), solid malignant tumors and malignant hematologic disorders ([@b42-bmi-2006-001]).

  Insulin                                                                             ✓                                                                             ✓                    2                     yes                         P01308                                                                                                                          Serum insulin levels were clearly higher in patients with breast cancer than in patients with benign breast disease and healthy controls ([@b111-bmi-2006-001]).

  Interferon gamma                                                                    ✓                                                           ✓                                      2                     yes                         P01579                    1.0E+01    ([@b18-bmi-2006-001])                                                                      An inflammatory cytokine decreased in squamous cell carcinoma of the head and neck ([@b185-bmi-2006-001]).

  Interleukin 2                                                                       ✓                                                           ✓                                      2                     yes                         P60568                    5.0E-01    ([@b185-bmi-2006-001])                                                                     A T cell growth factor with roles in the specific immune system, expression of IL-2 is high in infiltrative breast tumors ([@b97-bmi-2006-001]).

  Interleukin 6                                                                       ✓                                                           ✓                                      2                     yes                         P05231                    5.0E+00    ([@b185-bmi-2006-001])                                                                     IL-6 is a cytokine that activates both innate and specific immune pathways. It is present in patients with metastatic renal ([@b358-bmi-2006-001]), prostate ([@b3-bmi-2006-001]), oral cavity and oropharyngeal squamous cell carcinoma ([@b315-bmi-2006-001]).

  k-ras                                                                               ✓                                                           ✓                                      2                     yes                         P01116                    1.7E+02    ([@b342-bmi-2006-001])                                                                     An oncogene product found in approximately 90% of human pancreatic cancer ([@b285-bmi-2006-001]). 22.5% of ovarian cancers expressed K-ras codon 12 point mutations ([@b294-bmi-2006-001]).

  Neprilysin, CD10                                                                    ✓                                                           ✓                                      2                     yes                         P08473                    2.5E+02    ([@b381-bmi-2006-001])                                                                     CD10 is a B cell linage marker demonstrated to be positive in endometrial stromal sarcoma ([@b226-bmi-2006-001]).

  Transferrin                                                                         ✓                                                           ✓                                      2                     yes                         P02787                    4.0E+09    ([@b317-bmi-2006-001])                                                                     A serum iron transporter found to be decreased in laryngeal cancer ([@b331-bmi-2006-001]).

  Trypsin                                                                             ✓                                                           ✓                                      2                     yes                         P07477                    9.9E+04    ([@b4-bmi-2006-001])                                                                       A hydrolytic enzyme whose activity was significantly lower in hepatocellular cancer tissue ([@b241-bmi-2006-001]) but not altered in pancreatic, stomach, colon, rectal, lung or breast adenocarcinomas.

  Tumor necrosis factor (TNF-alpha)                                                   ✓                                                           ✓                                      2                     yes                         P01375                    5.9E+00    ([@b318-bmi-2006-001])                                                                     TNF-alpha is a proinflammatory protein detected in the serum of 36.5% of pancreatic cancer patients. Patients with metastatic disease showed significantly higher positive serum TNF-alpha compared to those with non-metastatic disease ([@b154-bmi-2006-001]).

  Tumor necrosis factor receptor superfamily member 6, fas                            ✓                                                           ✓                                      2                     yes                         P25445                    1.5E+03    ([@b117-bmi-2006-001])                                                                     An apoptosis death receptor whose soluble form has been shown to be increased in serum from ovarian ([@b117-bmi-2006-001]), hepatocellular ([@b282-bmi-2006-001]), bladder ([@b229-bmi-2006-001]), and colon cancer patients ([@b178-bmi-2006-001]).

  Von Willebrand Factor                                                               ✓                                                           ✓                                      2                     yes                         P04275                    1.1E+05    ([@b44-bmi-2006-001])                                                                      A coagulation factor that reflects endothelial damage ([@b327-bmi-2006-001]), it is elevated in patients with colorectal cancer ([@b66-bmi-2006-001]).

  Chemokine ligand 5 (CCL5)                                                                                                    ✓                  ✓                                      2                     yes                         P13501                    3.7E+04    ([@b25-bmi-2006-001])                                                                      A CC chemokine involved in both cellular and humoral immunity. It is expressed by leukemic cells in peripheral blood and lymph nodes from patients with adult T-cell leukemia, an HTLV-I associated disease ([@b235-bmi-2006-001]).

  Chitinase-3 like protein 1, YKL-40                                                                                           ✓                  ✓                                      2                     NF                          P36222                    2.8E+04    ([@b81-bmi-2006-001])                                                                      YKL-40 (cartilage gp-39), is a mammalian glycoprotein related in sequence to chitinases. Its function is unknown, but it is thought to be involved in tissue remodeling ([@b69-bmi-2006-001]). YKL-40 may represent a novel marker for the detection of early-stage ovarian cancer ([@b81-bmi-2006-001]).

  Choriogonadotropin beta chain                                                                                                                   ✓                 ✓                    2                     yes                         P01233                    1.0E+02    \<1.08 microg/ L, total protein ([@b276-bmi-2006-001]) beta chain ([@b212-bmi-2006-001])   The beta chain of choriogonadotropin supports pregnancy and can be seen in gestational trophoblastic disease, gestational trophoblastic neoplasm, choriocarcinoma and placental site tumor cases as well as in testicular cancer and germ cell tumor ([@b60-bmi-2006-001]).

  Colony stimulating factor 1 (macrophage)                                                                                                        ✓                 ✓                    2                     yes                         P09603                    7.0E+01    ([@b363-bmi-2006-001])                                                                     A modulator that increases production of inflammatory leukocytes from the bone marrow, it is increased in ovarian cancer ([@b308-bmi-2006-001]).

  Haptoglobin-1                                                                                                                ✓                  ✓                                      2                     yes                         P00738                    1.3E+09    ([@b37-bmi-2006-001])                                                                      It binds hemoglobin and is increased in conditions with extensive tissue damage and necrosis. It is increased in leukemia patients ([@b180-bmi-2006-001]). High levels in small cell lung cancer are associated with decreased survival ([@b34-bmi-2006-001]).

  Hepatocyte growth factor                                                                                                                        ✓                 ✓                    2                     yes                         P14210                    2.0E+02    ([@b215-bmi-2006-001])                                                                     A growth factor for a broad spectrum of tissues and cell types. Hepatocyte growth factor has no detectable protease activity. It is increased in breast cancer tissues ([@b255-bmi-2006-001]).

  Inhibin                                                                                                                                         ✓                 ✓                    2                     yes                         various                   3.0E+03    ([@b159-bmi-2006-001])                                                                     A glycoprotein hormone which regulates pituitary FSH, it is increased in postmenopausal ovarian cancer patients ([@b159-bmi-2006-001]).

  Interferon-alpha/beta receptor alpha chain                                                                                   ✓                  ✓                                      2                     yes                         P17181                    1.7E+03    ([@b150-bmi-2006-001])                                                                     IFN receptor activation inhibits viral replication. In increasing order, higher levels are seen in benign hypertrophy, urolithiasis, bladder cancer , renal cell carcinoma, and prostate cancer ([@b150-bmi-2006-001]). Concentrations for the complexed receptor.

  Interferon-alpha/beta receptor beta chain                                                                                    ✓                  ✓                                      2                     yes                         P48551                    1.7E+03    receptor ([@b150-bmi-2006-001])                                                            IFN receptor activation inhibits viral replication. In increasing order, higher levels are seen in benign hypertrophy, urolithiasis, bladder cancer, renal cell carcinoma, and prostate cancer ([@b150-bmi-2006-001]). Concentrations for the complexed receptor.

  Kallikrein 10                                                                                                                                   ✓                 ✓                    2                     yes                         O43240                    4.4E+02    ([@b204-bmi-2006-001])                                                                     Kallikrein 10 suppresses breast and prostate cancer. It is increased in tissues and serum of patients with ovarian cancer ([@b377-bmi-2006-001]).

  Kallikrein 11                                                                                                                                   ✓                 ✓                    2                     yes                         Q9UBX7                    2.2E+06    ([@b73-bmi-2006-001])                                                                      A serine protease that may be involved in tissue remodeling and cell migration, it is elevated in ovarian cancer ([@b378-bmi-2006-001]).

  Kallikrein 6                                                                                                                                    ✓                 ✓                    2                     yes                         Q92876                    2.9E+03    ([@b74-bmi-2006-001])                                                                      A serine protease that may be useful in the diagnosis and monitoring of ovarian and prostate cancer ([@b377-bmi-2006-001]). Increased plasma levels are also present in Alzheimer's disease ([@b75-bmi-2006-001]).

  Matrix metalloproteinase 3                                                                                                   ✓                  ✓                                      2                     yes                         P08254                    8.0E+03    ([@b288-bmi-2006-001])                                                                     A secreted proteoglycanase produced predominantly by connective tissue cells. MMPs are capable of disintegrating the basement membrane, which is a main characteristic of tumor invasion. MMP3 is elevated in squamous cell carcinomas of the head and neck. Additionally MMP3 is not changed in inflammatory diseases ([@b177-bmi-2006-001]).

  Small inducible cytokine A21 (CCL21)                                                                                         ✓                  ✓                                      2                     yes                         O00585                    1.7E+02    R&D                                                                                        CCL21 inhibits hematopoiesis and stimulates chemotaxis. It is differentially expressed in ovarian cancer ([@b233-bmi-2006-001]).

  soluble IL-2R alpha                                                                                                                             ✓                 ✓                    2                     yes                         P01589                    1.4E+03    ([@b30-bmi-2006-001])                                                                      The IL-2 receptor is required for T cell activation. The preoperative levels of serum soluble IL-2R in patients with colorectal cancer were significantly higher than those of normal controls. The levels of serum soluble IL-2R in patients with metastatic lymph nodes were also significantly higher than the levels in those without metastatic lymph nodes ([@b284-bmi-2006-001]).

  Somatotropin growth factor, growth hormone                                                                                                      ✓                 ✓                    2                     yes                         P01241\                   4.0E+02    ([@b174-bmi-2006-001])                                                                     Somatotropin controls growth. T is increased in gastrointestinal cancer patients ([@b80-bmi-2006-001]).
                                                                                                                                                                                                                                           P01242                                                                                                                          

  Breast cancer 2 early onset                                                         ✓                                                                                                  1                     yes                         P51587                                                                                                                          BRCA2 is a breast cancer susceptibility gene. Five percent of early onset breast cancer cases express mutations in Brca 1 or 2 ([@b184-bmi-2006-001]).

  Catenin Beta 1                                                                      ✓                                                                                                  1                     yes                         P35222                                                                                                                          Beta-catenin is necessary for the establishment and maintenance of epithelial layers. Accumulated cytoplasmic beta-catenin has been seen in esophageal squamous cell carcinoma ([@b383-bmi-2006-001]).

  Cathepsin D                                                                         ✓                                                                                                  1                     yes                         P07339                                                                                                                          A lysosomal proteinase, cathepsin D was found to be statistically significantly higher in colorectal cancer ([@b108-bmi-2006-001]).

  CD15                                                                                ✓                                                                                                  1                     yes                         x                                                                                                                               CD15 is a myeloid-associated surface antigen expressed on some myelomatous B cells and may be related to a poor prognosis ([@b280-bmi-2006-001]).

  Desmin                                                                              ✓                                                                                                  1                     yes                         P17661                                                                                                                          Desmin is a muscle-specific cytoskeletal protein found in smooth, cardiac, and heart muscles. 855 of mesothelial hyperplasias showed desmin immunoreactivity ([@b22-bmi-2006-001]).

  DNA-(apurinic or apyrimidinic site) lyase, APEX                                     ✓                                                                                                  1                     yes                         P27695                                                                                                                          A DNA repair enzyme, increased immuno histochemical staining seen in prostate cancer tissue ([@b158-bmi-2006-001]).

  Lutropin beta chain, Luteinizing hormone                                            ✓                                                                                                  1                     yes                         P01229                                                                                                                          A gonadotropic hormone decreased in breast cancer ([@b225-bmi-2006-001]).

  Parathyroid Hormone                                                                 ✓                                                                                                  1                     yes                         P01270                                                                                                                          Stimulates bone formation A correlation between tumor activity and ACTH, CT and PTH levels was shown in 50.44 and 47% of lung cancer patients respectively ([@b23-bmi-2006-001]).

  Proliferating cell nuclear antigen                                                  ✓                                                                                                  1                     yes                         P12004                                                                                                                          A DNA repair protein. Increased levels in breast cancer ([@b179-bmi-2006-001]).

  Tumor necrosis factor ligand superfamily member 8 (CD30 ligand)                     ✓                                                                                                  1                     yes                         P32971                                                                                                                          CD30L is a cell surface activation antigen on monocytes, T and B cells; and constitutively expressed on granulocytes and medullary thymic epithelial cells. It is expressed in thyroid cancer tissue ([@b341-bmi-2006-001]).

  V-myc myelocytomatosis viral oncogene homolog (avian)                               ✓                                                                                                  1                     yes                         P01106                                                                                                                          An oncogene whose increased transcriptional activity is a characteristic feature of Burkitt's lymphoma ([@b361-bmi-2006-001]).

  Tumor necrosis factor ligand superfamily member 8 (CD30)                            ✓                                                                                                  1                     yes                         P28908                                                                                                                          A lymphoid activation antigen overexpressed in Hodgkin's disease ([@b133-bmi-2006-001]).

  17beta- Hydroxysteroid dehydrogenase type 1 (17HSD1)                                                                         ✓                                                         1                     NF                          x                                                                                                                               17HSD1 converts estrone to estradiol in the ovary, placenta and the breast. Signals for 17HSD1 mRNA were detected in 16% of breast cancer specimens ([@b248-bmi-2006-001]).

  Acid phosphatase prostate                                                                                                                       ✓                                      1                     yes                         P15309                    3.5E+03    ([@b183-bmi-2006-001])                                                                     An enzyme produced by the prostate, it is increased in men with prostate cancer ([@b5-bmi-2006-001]).

  Adrenomedullin                                                                                                                                  ✓                                      1                     yes                         P35318                    7.4E+01    ([@b84-bmi-2006-001])                                                                      Adrenomedullin is a hypotensive peptide increased in gastrointestinal tract and lung cancer ([@b84-bmi-2006-001]).

  Aldolase A                                                                                                                                      ✓                                      1                     yes                         P04075                    1.7E+05    ([@b236-bmi-2006-001])                                                                     A housekeeping gene differentially expressed during development and increased in ovarian ([@b339-bmi-2006-001]) and renal cell cancer ([@b384-bmi-2006-001]).

  Alkaline phosphatase bone-specific                                                                                                              ✓                                      1                     NF                          P05186                    4.1E+04    ([@b210-bmi-2006-001])                                                                     Bone specific alkaline phosphatase may play a role in skeletal mineralization. Bone-specific alkaline phosphatase was significantly increased in prostate cancer patients with bone metastases compared to patients without metastases ([@b148-bmi-2006-001]).

  Alkaline phosphatase, placental type                                                                                                                              ✓                    1                     yes                         P05187                                                                                                                          An oncodevelopmental protein, PLAP was not detected in any of the 22 controls or 12 glioma patients, but high PLAP levels were detected in all 15 germinoma patients, with values ranging from 15 to 3700 pg/ml ([@b359-bmi-2006-001]).

  Alpha-1-acid glycoprotein 1, orosomucoid                                                                                                        ✓                                      1                     yes                         P02763                    6.9E+08    ([@b183-bmi-2006-001])                                                                     An acute phase protein showing a 3--4 fold increase during inflammation or tissue damage, levels peak 3--5 days after the initiating event. It is increased in breast cancer ([@b334-bmi-2006-001]).

  Alpha-1-antitrypsin                                                                                                                             ✓                                      1                     yes                         P01009                    1.4E+09    ([@b183-bmi-2006-001])                                                                     A protease inhibitor and marker of malignant histiocytes ([@b223-bmi-2006-001]).

  alpha-2-HS-glycoprotein                                                                                                                         ✓                                      1                     yes                         P02765                    6.1E+08    ([@b76-bmi-2006-001])                                                                      Promotes endocytosis, possesses opsonic properties and plays a role in bone metabolism; it is decreased in leukemia patients ([@b180-bmi-2006-001]).

  Alpha-2-macroglobulin                                                                                                                           ✓                                      1                     yes                         P01023                    1.8E+09    ([@b183-bmi-2006-001])                                                                     A serum plasma proteinase inhibitor with a wide specificity, it is decreased in prostate cancer with metastases ([@b151-bmi-2006-001]).

  Alpha-lactalbumin                                                                                                                               ✓                                      1                     NF                          P00709                    2.0E+04    ([@b165-bmi-2006-001])                                                                     The principle milk protein that functions in the synthesis of lactose, it is increased in some breast cancer patients ([@b352-bmi-2006-001]).

  Angiogenin ribonuclease RNase A family 5                                                                                                        ✓                                      1                     yes                         P03950                    4.0E+05    ([@b256-bmi-2006-001])                                                                     An angiogenesis protein increased in pancreatic, stomach, kidney, invasive bladder, colorectal, breast, ovarian, endometrial, uterine, cancer and melanoma ([@b256-bmi-2006-001]).

  Angiopoietin 1                                                                                                                                  ✓                                      1                     yes                         Q15389                    4.0E+03    ([@b45-bmi-2006-001])                                                                      Involved in vasculature modeling, it is increased in breast cancer ([@b45-bmi-2006-001]).

  Angiopoietin 2                                                                                                                                  ✓                                      1                     yes                         O15123                    1.5E+03    ([@b45-bmi-2006-001])                                                                      It is involved in vasculature modeling in that it is an antagonist of angiopoietin 2. It is increased in breast cancer ([@b45-bmi-2006-001]).

  Antileukoproteinase 1, SLPI                                                                                                                     ✓                                      1                     yes                         P03973                    3.2E+04    ([@b346-bmi-2006-001])                                                                     An acid-stable proteinase inhibitor with strong affinity for trypsin and chymotrypsin as well as for neutrophil lysosomal elastase and cathepsin G, it is elevated in ovarian cancer patients ([@b346-bmi-2006-001]).

  Apolipoprotein A1                                                                                                                               ✓                                      1                     yes                         P02647                    1.4E+09    ([@b100-bmi-2006-001])                                                                     Apolipoprotein A-I is the major apoprotein of HDL. ApoA-I also promotes efflux of cholesterol from cell. It is decreased ovarian cancer ([@b382-bmi-2006-001]).

  Apolipoprotein A-II                                                                                                                             ✓                                      1                     yes                         P02652                    2.4E+08    \#N/A                                                                                      Associates with, stabilizes and regulates metabolism of HDL. ApoA-II is overexpressed both in tissues and serum from individuals with prostate cancer. ApoA-II was also overexpressed in the serum of individuals with prostate cancer who have normal prostate-specific antigen (0--4.0 ng/mL) ([@b211-bmi-2006-001]).

  Apolipoprotein C-I                                                                                                                              ✓                                      1                     yes                         P02654                    6.1E+07    ([@b272-bmi-2006-001])                                                                     The smallest of the apolipoproteins, lipid metabolism regulators, the Apo-CI gene is upregulated in gastric cancer ([@b372-bmi-2006-001]).

  Apolipoprotein C-III                                                                                                                            ✓                                      1                     yes                         P02656                    1.2E+08    ([@b253-bmi-2006-001])                                                                     It delays the catabolism of triglyceride-rich particles and is decreased in myeloid leukemia patients ([@b180-bmi-2006-001]).

  Bone sialoprotein II                                                                                                                            ✓                                      1                     yes                         P21815                    1.5E+05    ([@b88-bmi-2006-001])                                                                      A noncollagenous bone protein increased in prostate, colon, and breast cancer ([@b88-bmi-2006-001]).

  Brain-derived neurotrophic factor                                                                                                               ✓                                      1                     yes                         P23560                    2.4E+04    R&D Quantikine kit                                                                         It promotes the survival of neuronal populations and is differentially expressed in ovarian cancer ([@b233-bmi-2006-001]).

  Breast cancer metastasis- suppressor 1                                                                                       ✓                                                         1                     yes                         Q9HCU\                                                                                                                          BRMS1 suppresses metastases. BRMS1 mRNA expression was high in melanocytes, considerably reduced in early melanoma-derived cell lines, and barely detectable in advanced/meta- static cell lines ([@b301-bmi-2006-001]).
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  CA 27.29                                                                                                                                                          ✓                    1                     NF                          x                                                                                                                               A monoclonal antibody identified cancer antigen most frequently used to follow response to therapy in patients with metastatic breast cancer ([@b257-bmi-2006-001]).

  CA 72--4                                                                                                                                                          ✓                    1                     NF                          x                                                                                                                               A monoclonal antibody identified cancer antigen useful in the diagnosis of breast ([@b308-bmi-2006-001]) and pancreatic cancer ([@b146-bmi-2006-001]).

  Cathepsin B                                                                                                                                     ✓                                      1                     yes                         P07858                    2.1E+03    ([@b172-bmi-2006-001])                                                                     A major cysteine protease involved in antigen degradation, it is overexpressed in tumors of the lung, prostate, colon, breast, stomach and esopha- geal adenocarcinoma ([@b137-bmi-2006-001]).

  CC chemokine 4, HCC-4                                                                                                                           ✓                                      1                     yes                         O15467                    1.1E+04    ([@b246-bmi-2006-001])                                                                     A chemotactic and myelosuppressive factor, differentially expressed in ovarian cancer ([@b233-bmi-2006-001]).

  CD44 variant V5 soluble                                                                                                                         ✓                                      1                     yes                         P16070                    3.3E+04    ([@b199-bmi-2006-001])                                                                     A lymphocyte homing receptor found in the serum of patients with malignant bone tumors ([@b132-bmi-2006-001]).

  Ceruloplasmin                                                                                                                                   ✓                                      1                     yes                         P00450                    2.8E+08    ([@b160-bmi-2006-001])                                                                     A copper binding plasma metalloprotein increased in laryngeal cancer patients ([@b331-bmi-2006-001]).

  Cervical cancer 1 protooncogene protein p40                                                                                                     ✓                                      1                     NF                          x                         1.5E+07    ([@b376-bmi-2006-001])                                                                     A protooncogene expressed in the plasma and tissues of hepatocellular cancer patients ([@b376-bmi-2006-001]).

  Chemokine (C-C motif) ligand 4 Small inducible cytokine A4 (CCL4), MIP-1-beta                                                                   ✓                                      1                     yes                         P13236                    7.0E+01    ([@b106-bmi-2006-001])                                                                     CCL4 is a protein that directs the migration of specific subsets of leukocytes. It is elevated in sera from large granular lymphocyte leukemia patients ([@b173-bmi-2006-001]).

  Claudin-3                                                                                                                    ✓                                                         1                     NF                          O15551                                                                                                                          Claudins are involved in the formation of TJ strands upregulated in ovarian cancer ([@b201-bmi-2006-001]).

  Claudin-4                                                                                                                    ✓                                                         1                     NF                          O14493                                                                                                                          Claudins are involved in the formation of TJ strands upregulated in ovarian cancer ([@b127-bmi-2006-001]).

  Clusterin                                                                                                                                       ✓                                      1                     yes                         P10909                    1.0E+08    ([@b129-bmi-2006-001])                                                                     Inhibits complement-mediated cytolysis. It is decreased in leukemia patients ([@b180-bmi-2006-001]).

  Coagulation factor III                                                                                                                          ✓                                      1                     yes                         P13726                    1.6E+02    ([@b207-bmi-2006-001])                                                                     Coagulation factor III initiates coagulation, it is upregulated in patients with malignancy-associated hypercoagulable state.

  Coagulation factor XIII A chain                                                                                                                 ✓                                      1                     yes                         P00488                    5.2E+06    ([@b156-bmi-2006-001])                                                                     The catalytic unit of factor XIII which crosslinks fibrin, is decreased in breast cancer tissues ([@b145-bmi-2006-001]).

  Coagulation factor XIII B chain                                                                                                                 ✓                                      1                     NF                          P05160                    4.8E+06    ([@b156-bmi-2006-001])                                                                     The protein carrier subunit of factor XIII, it crosslinks fibrin. It is decreased in breast cancer tissues ([@b145-bmi-2006-001]).

  Collagen I c-terminal telopeptide                                                                                                               ✓                                      1                     NF                          P02452                    2.9E+02    ([@b210-bmi-2006-001])                                                                     Collagen is a structural protein, the c-terminal telopeptide is increased in patients with prostate cancer and bone metastasis ([@b98-bmi-2006-001]).

  Complement component 3                                                                                                                          ✓                                      1                     yes                         x                         1.3E+09    ([@b183-bmi-2006-001])                                                                     An effector of innate and adaptive immunity, it is increased in renal carcinoma patients ([@b131-bmi-2006-001]).

  Complement component 4                                                                                                                          ✓                                      1                     NF                          x                         2.3E+08    ([@b287-bmi-2006-001])                                                                     An effector of innate and adaptive immunity, it is increased in renal carcinoma patients ([@b131-bmi-2006-001]).

  Complement component 7                                                                                                                          ✓                                      1                     yes                         P10643                    5.2E+07    ([@b183-bmi-2006-001])                                                                     An effector of innate and adaptive immunity, its mRNA is decreased in oesophageal, colon and kidney cancers ([@b250-bmi-2006-001]).

  Complement factor H related protein                                                                                                                               ✓                    1                     NF                          Q03591                                                                                                                          Complement factor H related protein is involved in complement regulation. It has a role in cancer surveillance and in the screening of high-risk asymptomatic bladder cancer patients ([@b263-bmi-2006-001]).

  Cyclin-dependent kinase 6                                                                                                    ✓                                                         1                     yes                         Q00534                                                                                                                          Cyclin-dependent kinase 6 links growth factor stimulation with the onset of cell cycle progression. Immunohistochemical studies showed reduced levels of cdk6 in breast tumor cells as compared with normal breast tissue in vivo ([@b202-bmi-2006-001]).

  Cyclooxygenase-2                                                                                ✓                                                                                      1                     yes                         P35354                                                                                                                          Cox-2 is induced by inflammation mediators and overexpressed in various cancers ([@b163-bmi-2006-001]).

  Cystatin A                                                                                                                                      ✓                                      1                     yes                         P01040                    3.2E+03    ([@b171-bmi-2006-001])                                                                     Inhibitor of the cysteine proteinase cathepsin B, it is increased in squamous cell carcinoma of the head and neck ([@b319-bmi-2006-001]).

  Cystatin B                                                                                                                                      ✓                                      1                     yes                         P04080                    1.7E+03    ([@b171-bmi-2006-001])                                                                     Inhibitor of the cysteine proteinases cathepsin L decreased in squamous cell carcinoma of the head and neck ([@b319-bmi-2006-001]).

  Cystatin C                                                                                                                                      ✓                                      1                     yes                         P01034                    3.2E+05    ([@b321-bmi-2006-001])                                                                     The most abundant extracellular inhibitor of cysteine proteases, it is produced in all organs. It is decreased in squamous cell carcinoma of the head and neck ([@b320-bmi-2006-001]) and in serum from ovarian cancer patients however, protein expression in ovarian cancer tissue is increased ([@b243-bmi-2006-001]).

  Cytokeratin 8                                                                                                                                   ✓                                      1                     yes                         P05787                    5.0E+04    ([@b92-bmi-2006-001])                                                                      A cytoskeleton protein differentially expressed in pancreatic cancer ([@b305-bmi-2006-001]).

  Diazepam binding inhibitor                                                                                                                      ✓                                      1                     yes                         P07108                    1.0E+00    ([@b24-bmi-2006-001])                                                                      DBI interacts with GABA receptors downregulating the inhibitory effects of GABA. It participates in the metabolism and genesis of steroids. DBI was found to be increased in the serum from Hepatocellular patients but decreased in their tissue ([@b355-bmi-2006-001]).

  Endoglin                                                                                                                                        ✓                                      1                     yes                         P17813                    3.4E+04    ([@b326-bmi-2006-001])                                                                     An angiogenesis factor increased in breast cancer ([@b192-bmi-2006-001]).

  Endothelin 1                                                                                                                                    ✓                                      1                     yes                         P05305                    1.5E+00    ([@b347-bmi-2006-001])                                                                     Endothelin is a vasoconstrictor significantly elevated in 80% of primary human colon cancers ([@b161-bmi-2006-001]).

  Epidermal growth factor                                                                                                                         ✓                                      1                     yes                         P01133                    1.5E+01    ([@b251-bmi-2006-001])                                                                     Epidermal growth factor stimulates the growth of various epidermal and epithelial tissues, it is differentially expressed in ovarian cancer ([@b233-bmi-2006-001]).

  E-selectin                                                                                                                                      ✓                                      1                     yes                         P16581                    9.2E+02    ([@b44-bmi-2006-001])                                                                      An adhesion molecule, sE-selectins increased in metastatic breast cancer especially in patients with liver metastases ([@b116-bmi-2006-001]).

  Ferritin H                                                                                                                                      ✓                                      1                     NF                          P02794                    5.0E+04    Ferritin ([@b125-bmi-2006-001])                                                            An iron storage protein secreted by hepatocellular tumors ([@b59-bmi-2006-001]). Several clinical conditions can give rise to increased serum ferritin levels in the absence of high iron stores, including cancer, inflammation, and infection ([@b125-bmi-2006-001]). Concentration is for complex protein.

  Ferritin, L                                                                                                                                     ✓                                      1                     yes                         P02792                    5.0E+04    Ferritin ([@b125-bmi-2006-001])                                                            The major intracellular iron storage protein, it is raised in hepatocellular cancer ([@b59-bmi-2006-001]), inflammation and infection ([@b125-bmi-2006-001]). Concentration is for complex protein.

  Fibroblast growth factor 2 (basic)                                                                                                              ✓                                      1                     yes                         P09038                    7.9E+00    ([@b312-bmi-2006-001])                                                                     Fibroblast growth factor is a wide-spectrum mitogenic, angiogenic, and neurotrophic factor elevated in advanced melanoma ([@b350-bmi-2006-001]) and myeloma ([@b297-bmi-2006-001]).

  Fibronectin 1                                                                                                                                   ✓                                      1                     yes                         P02751                    4.0E+05    ([@b119-bmi-2006-001])                                                                     Thought to have a role in cell adhesion, morphology, surface architecture and contact inhibition. It is increased in renal cell cancer being highest in metastatic disease ([@b118-bmi-2006-001]).

  Flt-3 ligand                                                                                                                                    ✓                                      1                     yes                         x                         4.0E+02    ([@b385-bmi-2006-001])                                                                     Flt-3 ligand promotes long-term expansion, differentiation and proliferation of some hematopoietic cells. Higher pretreatment serum levels of Flt3L in lymphoma are associated with higher stage (\> or = II) and higher grade ([@b268-bmi-2006-001]).

  Fms-related tyrosine kinase 1, VEGFR1                                                                                                           ✓                                      1                     yes                         P17948                    3.0E+04    ([@b45-bmi-2006-001])                                                                      An oncogene that is important for the control of cell proliferation and differentiation, it is reduced in breast cancer ([@b45-bmi-2006-001]).

  Follistatin                                                                                                                                     ✓                                      1                     NF                          P19883                    6.8E+02    ([@b136-bmi-2006-001])                                                                     An activin antagonist, follistatin inhibits the biosynthesis and secretion of pituitary follicle stimulating hormone. It is differentially expressed in ovarian cancer ([@b233-bmi-2006-001]).

  Fructose- bisphosphate aldolase B                                                                                                               ✓                                      1                     NF                          P05062                    2.0E+04    ([@b19-bmi-2006-001])                                                                      A housekeeping gene differentially expressed during development decreased in renal cell cancer ([@b384-bmi-2006-001]) and malignant liver tumor patients ([@b19-bmi-2006-001]).

  Fructose- bisphosphate aldolase C                                                                                                               ✓                                      1                     NF                          P09972                    2.0E+04    ([@b20-bmi-2006-001])                                                                      A housekeeping gene differentially expressed during development, it is increased in renal cell cancer ([@b384-bmi-2006-001]).

  Geminin                                                                                                                      ✓                                                         1                     NF                          O75496                                                                                                                          Geminin is a potent inhibitor of origin assembly and re-replication in multicellular eukaryotes and is a negative regulator of DNA replication during the cell cycle. Geminin expression is increased in 56% and of colon cancers, 58% of rectal cancers, and 60% of human primary breast cancers ([@b231-bmi-2006-001]).

  Glucose-6- phosphate isomerase                                                                                                                  ✓                                      1                     NF                          P06744                    5.5E+07    ([@b102-bmi-2006-001])                                                                     A glycolytic enzyme elevated inovarian cancer ([@b374-bmi-2006-001]).

  Glypican-3, n-terminal                                                                                                                          ✓                                      1                     yes                         P51654                    6.5E+02    ([@b128-bmi-2006-001])                                                                     Glypican-3 may be involved in the modulation of growth. It is increased in hepatocellular cancer ([@b128-bmi-2006-001]).

  Growth arrest and DNA-damage- inducible alpha                                                                                ✓                                                         1                     yes                         P24522                                                                                                                          GADD45A is strongly induced by ultraviolet radiation and alkylating agents and may be an effector of processes that regulate prostate cancer cell survival ([@b298-bmi-2006-001]).

  Immunosuppressive acidic protein                                                                                                                ✓                                      1                     NF                          x                         6.2E+08    ([@b214-bmi-2006-001])                                                                     An immunosuppressive molecule and prognostic marker in patients with renal cell carcinoma ([@b216-bmi-2006-001]).

  Insulin-like growth factor 1 (somatomedin C)                                                                                                    ✓                                      1                     yes                         P01343                    2.1E+05    ([@b316-bmi-2006-001])                                                                     Insulin-like growth factor 1 plays an important role in growth and development. It is decreased in endometrial cancer ([@b249-bmi-2006-001]) and Non-Hodgkins' Lymphoma ([@b230-bmi-2006-001]) but increased in prostate cancer ([@b316-bmi-2006-001]).

  Insulin-like growth factor 2 (somatomedin A)                                                                                                    ✓                                      1                     yes                         P01344                    3.8E+05    ([@b249-bmi-2006-001])                                                                     Significantly increased in women with ([@b249-bmi-2006-001]) but decreased in children with leukemia, Non-Hodgkins' Lymphoma (NHL) or solid tumors at the time of diagnosis ([@b230-bmi-2006-001]).

  Insulin-like growth factor binding protein 1                                                                                                    ✓                                      1                     yes                         P24591                    1.1E+05    ([@b55-bmi-2006-001])                                                                      Insulin-like growth factor binding proteins carry insulin-like growth factor thereby regulating its activity. It is differentially expressed in ovarian cancer ([@b233-bmi-2006-001]).

  Insulin-like growth factor binding protein 2                                                                                                    ✓                                      1                     yes                         P18065                    3.1E+05    ([@b336-bmi-2006-001])                                                                     Insulin-like growth factor binding proteins carry insulin-like growth factor thereby regulating its activity. IGFBP-2 is elevated in Non-Hodgkins' Lymphoma ([@b230-bmi-2006-001]).

  Insulin-like growth factor binding protein 3                                                                                                    ✓                                      1                     yes                         P17936                    2.5E+06    ([@b316-bmi-2006-001])                                                                     Insulin-like growth factor binding proteins carry insulin-like growth factor thereby regulating its activity. It is decreased in endometrial cancer ([@b249-bmi-2006-001]) and Non-Hodgkins' Lymphoma ([@b230-bmi-2006-001]) but increased in prostate cancer ([@b316-bmi-2006-001]).

  Intercellular Adhesion Molecule 1                                                                                                               ✓                                      1                     yes                         P05362                    2.1E+05    ([@b190-bmi-2006-001])                                                                     A lymphocyte adhesion molecule elevated in melanoma ([@b40-bmi-2006-001]), hepatocellular cancer ([@b345-bmi-2006-001]), breast cancer ([@b13-bmi-2006-001]), and extranodal lymphomas ([@b190-bmi-2006-001]).

  Interferon alpha 1                                                                                                                              ✓                                      1                     yes                         P01562                    4.5E+01    ([@b183-bmi-2006-001])                                                                     An antiviral cytokine that promotes cell-mediated immunity against intracellular microbes, it is differentially expressed in leukemia ([@b126-bmi-2006-001]).

  Interleukin 1 alpha                                                                                                                             ✓                                      1                     yes                         P01583                    3.0E+00    ([@b325-bmi-2006-001])                                                                     An inflammation and innate immunity modulator, IL-1 alpha is increased in ovarian cancer ([@b167-bmi-2006-001]).

  Interleukin 1 beta                                                                                                                              ✓                                      1                     yes                         P01584                    5.0E+00    ([@b185-bmi-2006-001])                                                                     IL-1 beta is an inflammation and innate immunity modulator, loss of activity seen in prostate cancer ([@b270-bmi-2006-001]).

  Interleukin 10                                                                                                                                  ✓                                      1                     yes                         P22301                    3.5E+00    ([@b185-bmi-2006-001])                                                                     IL-10 a suppressive cytokine, is increased in melanoma patients with metastases and poorer prognosis ([@b40-bmi-2006-001]).

  Interleukin 12A                                                                                                                                 ✓                                      1                     yes                         P29459                    3.9E+00    ([@b183-bmi-2006-001])                                                                     IL-12 is involved in innate and specific immune responses, levels were lower in malignant glioma ([@b286-bmi-2006-001]).

  Interleukin 16                                                                                                                                  ✓                                      1                     yes                         Q14005                    1.0E+02    ([@b12-bmi-2006-001])                                                                      Interleukin 16 is a chemotactic cytokine increased in multiple myeloma ([@b12-bmi-2006-001]).

  Interleukin 5                                                                                                                                   ✓                                      1                     yes                         P05113                    8.0E+00    ([@b183-bmi-2006-001])                                                                     IL-5 is an inflammation marker that links T cell activation with eosinophils which are responsible for clearing of parasites. It is increased in Hodgkin's disease ([@b71-bmi-2006-001]).

  Interleukin 6 receptor                                                                                                                          ✓                                      1                     yes                         P08887                    4.5E+02    ([@b11-bmi-2006-001])                                                                      An inflammation marker receptor that regulates the immune response, acute-phase reactions and hematopoiesis, it is significantly elevated in multiple myeloma patients ([@b11-bmi-2006-001]). IL6 receptor mRNA was detected in 53% of breast carcinoma tissues and is associated with earlier stages of the disease. In advanced stages, expression of IL-6 and its receptor subunits predicts better prognosis ([@b155-bmi-2006-001]).

  Interleukin 6 signal transducer                                                                                                                 ✓                                      1                     NF                          P40189                    2.7E+05    ([@b193-bmi-2006-001])                                                                     A signal transducer molecule, increased in breast cancer ([@b155-bmi-2006-001]).

  Interleukin 7                                                                                                                                   ✓                                      1                     yes                         P13232                    1.1E+01    ([@b367-bmi-2006-001])                                                                     Il-7 stimulates hematopoiesis, it is increased in ovarian cancer ([@b367-bmi-2006-001]).

  Interleukin 8                                                                                                                                   ✓                                      1                     yes                         P10145                    8.3E+01    ([@b267-bmi-2006-001]) ([@b106-bmi-2006-001])                                              Il-8 is a chemotactic factor. Elevated serum concentrations were associated with advanced disease stages and melanoma tumor burden ([@b350-bmi-2006-001]).

  Interleukin 9                                                                                                                                   ✓                                      1                     yes                         P15248                    6.0E+00    ([@b89-bmi-2006-001])                                                                      IL-9 supports growth of some immune cells, it is increased in Hodgkin's lymphoma ([@b89-bmi-2006-001]).

  Interleukin-1 receptor antagonist protein, IRAP                                                                                                 ✓                                      1                     yes                         P18510                    1.6E+03    ([@b183-bmi-2006-001])                                                                     An acute phase protein that is antagonistic to IL alpha and beta, it is downregulated in oesophageal adenocarcinoma ([@b134-bmi-2006-001]).

  Kallikrein 14 (hK14)                                                                                                                            ✓                                      1                     yes                         Q9P0G3                    1.6E+02    ([@b39-bmi-2006-001]) in male serum female serum negative                                  Kallikrein 14 is a serine protease increased in 40% of ovarian cancer tissues and elevated in the serum of a proportion of patients with ovarian (65%) and breast (40%) cancers ([@b39-bmi-2006-001]).

  Kallikrein 2 prostatic                                                                                                                          ✓                                      1                     NF                          P20151                    2.2E+01    ([@b351-bmi-2006-001])                                                                     A serine endopeptidase, kallikrein 2 may predict pathologically organ confined prostate cancer in patients with stage T2 disease but not in stageT1c ([@b109-bmi-2006-001]).

  Kallikrein 5                                                                                                                                                      ✓                    1                     yes                         Q9Y337                                                                                                                          Kallikrein 5 is a peptidase increased in ovarian cancer tissues ([@b378-bmi-2006-001]).

  Kallikrein 7                                                                                                                                                      ✓                    1                     NF                          P49862                                                                                                                          Kallikrein 7 is a peptidase increased in ovarian cancer tissues ([@b378-bmi-2006-001]).

  Kallikrein 8                                                                                                                                                      ✓                    1                     yes                         O60259                                                                                                                          Kallikrein 8 is a peptidase increased in ovarian cancer tissues ([@b378-bmi-2006-001]).

  Keratin 18                                                                                                                                      ✓                                      1                     yes                         P05783                    4.0E+03    ([@b264-bmi-2006-001])                                                                     Keratin 18 is one of the first intermediate filament proteins expressed in the embryo. A monoclonal antibody to epithelium-specific keratin 18 stained the majority of inner cells in benign breast lesions but comparatively fewer such cells in carcinoma in situ and invasive carcinoma ([@b279-bmi-2006-001]).

  Keratin, type I cytoskeletal 19, cytokeratin 19                                                                                                 ✓                                      1                     yes                         P08727                    2.4E+03    ([@b112-bmi-2006-001])                                                                     A cytoskeleton protein increased in bladder ([@b237-bmi-2006-001]) and breast cancer ([@b105-bmi-2006-001]).

  Kit ligand                                                                                                                                      ✓                                      1                     yes                         P21583                    3.3E+05    ([@b38-bmi-2006-001])                                                                      A hematopoietic growth factor, decreased in patients with gastrointestinal stromal tumors ([@b38-bmi-2006-001]).

  Lactotransferrin                                                                                                                                ✓                                      1                     yes                         P02788                    2.7E+05    ([@b352-bmi-2006-001])                                                                     An iron-binding protein that modulates iron metabolism, hematopoiesis, and immunologic reactions. It is increased in gastrointestinal, lung and breast cancer patients ([@b352-bmi-2006-001]).

  Leptin                                                                                                                                          ✓                                      1                     yes                         P41159                    4.8E+03    ([@b78-bmi-2006-001])                                                                      Leptin plays a critical role in the regulation of body weight and is decreased in gastrointestinal carcinomas ([@b80-bmi-2006-001]).

  L-selectin                                                                                                                                      ✓                                      1                     yes                         P14151                    6.0E+05    ([@b21-bmi-2006-001])                                                                      An adhesion molecule elevated in non-Hodgkin's lymphoma and Hodgkin's disease ([@b115-bmi-2006-001]).

  Luteinizing hormone-releasing hormone receptor                                                                                                                    ✓                    1                     NF                          x                                                                                                                               A growth inhibiting tyrosine phosphatase found in 29 of 37 (78.4%) ovarian cancers and in 6 of 11 (54.5%) non-malignant human ovaries ([@b314-bmi-2006-001]).

  Mac-2 Binding Protein 90K                                                                                                                       ✓                                      1                     NF                          Q08380                    9.1E+06    ([@b139-bmi-2006-001])                                                                     Promotes integrin-mediated cell adhesion, it is increased in breast ([@b138-bmi-2006-001]) and hepatocellular cancer ([@b139-bmi-2006-001]).

  Mammaglobin B                                                                                                                ✓                                                         1                     NF                          O75556                                                                                                                          Mammaglobin B may bind androgens and other steroids, it shows high sequence similarity to mammaglobin. Frequently upregulated in lung tumors ([@b307-bmi-2006-001]).

  Mammary Serum Antigen                                                                                                                                                                  0                     NF                          x                         4.0E+05    ([@b309-bmi-2006-001])                                                                     A serum glycoprotein on breast cancer cells detectable in serum. It may be an early prognostic marker in breast cancer ([@b309-bmi-2006-001]).

  Mast/stem cell growth factor receptor                                                                                                           ✓                                      1                     NF                          P10721                    3.3E+05    ([@b38-bmi-2006-001])                                                                      A proto-oncogene tyrosine-protein kinase expressed in acute promyelocytic leukemia ([@b274-bmi-2006-001]) and in the serum of gastrointestinal stromal tumor patients ([@b38-bmi-2006-001]).

  Matrix metalloproteinase 2                                                                                                                      ✓                                      1                     yes                         P08253                    1.0E+05    ([@b290-bmi-2006-001])                                                                     A metalloproteinase that specifically cleaves type IV collagen, the major structural component of basement membranes. The metastatic potential of tumor cells has been found to correlate with the activity of this enzyme. It is markedly elevated in colorectal cancer patients ([@b79-bmi-2006-001]).

  Matrix metalloproteinase 9                                                                                                                      ✓                                      1                     yes                         P14780                    1.9E+05    ([@b271-bmi-2006-001])                                                                     MMPs are capable of disintegrating the basement membrane, which is a main characteristic of tumor invasion. MMP9 was significantly increased in patients with squamous cell cancer of the head and neck over controls. It was not changed in inflammatory diseases ([@b177-bmi-2006-001]).

  Melanoma-inhibiting activity                                                                                                                    ✓                                      1                     NF                          Q16674                    8.8E+03    ([@b85-bmi-2006-001])                                                                      A protein secreted by malignant melanoma cells that elicits growth inhibition of melanoma cells in vitro. Elevated levels predict a poor prognosis ([@b85-bmi-2006-001]).

  Membrane cofactor protein, CD46 antigen                                                                                                         ✓                                      1                     NF                          P15529                    3.5E+04    ([@b296-bmi-2006-001])                                                                     A membrane protein that protects host cells from complement damage. Normal human sera contained 10--60 ng/ml of soluble membrane cofactor protein whereas sera of \> 50% of cancer patients contained \> 60 ng/ml ([@b296-bmi-2006-001]).

  Mesothelin                                                                                                                                                        ✓                    1                     NF                          Q13421                                                                                                                          A differentiation antigen, overexpressed in several human tumors ([@b113-bmi-2006-001]).

  Midkine                                                                                                                                         ✓                                      1                     NF                          P21741                    1.5E+02    ([@b141-bmi-2006-001])                                                                     Midkine has heparin binding activity, and growth promoting activity, it is increased in breast cancer patients ([@b141-bmi-2006-001]).

  MK-1 protein, Ep-CAM                                                                                                                            ✓                 ✓                    1                     yes                         x                         2.0E+03    ([@b1-bmi-2006-001])                                                                       A membrane glycoprotein that is overexpressed on the majority of tumor cells of epithelial origin, it is increased in the serum from patients with malignant tumors of various tissue origins ([@b1-bmi-2006-001]).

  Myoblast determination protein 1                                                                                             ✓                                                         1                     yes                         P15172                                                                                                                          A myogenic transcriptional regulatory protein expressed early in skeletal muscle differentiation, it is considered a sensitive and specific marker for Rhabdomyosarcoma and is more specific than desmin and muscle-specific actin and more sensitive than myoglobin ([@b47-bmi-2006-001]).

  Nerve growth factor beta                                                                                                                        ✓                                      1                     yes                         P01138                    7.0E+02    ([@b269-bmi-2006-001])                                                                     Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems. Immunostaining for nerve growth factor-beta in esophageal and breast carcinomas demonstrated its immunoreactivity in stromal fibroblasts and some TrkA-expressing tumor cells ([@b164-bmi-2006-001]).

  Netrin-1                                                                                                                     ✓                                                         1                     NF                          O95631                                                                                                                          Signals axon growth and guidance. A reduction of NTN1 expression was observed in prostate tumors ([@b186-bmi-2006-001]).

  Neuroendocrine secretory protein-55                                                                                          ✓                                                         1                     NF                          x                                                                                                                               A peptidergic marker for a large constitutively secreting vesicle pool found in the central and peripheral nervous system, NESP-55 reactivity is restricted to endocrine tumors of the pancreas and the adrenal medulla ([@b313-bmi-2006-001]).

  Neutrophil defensin 1                                                                                                                           ✓                                      1                     yes                         P59665                    4.2E+04    all defensins measured together ([@b254-bmi-2006-001])                                     An antimicrobial protein secreted by neutrophils increased in colon cancer patients ([@b10-bmi-2006-001]). Concentration given is for all three defensins together 1,2 & 3.

  Neutrophil defensin 3                                                                                                                           ✓                                      1                     yes                         P59666                    4.2E+04    all defensins measured together ([@b254-bmi-2006-001])                                     An antimicrobial protein secreted by neutrophils increased in colon cancer patients ([@b10-bmi-2006-001]). Concentration given is for all three defensins together 1,2 & 3.

  Nm23-H1                                                                                                                                         ✓                                      1                     yes                         P15531                    6.1E+03    ([@b252-bmi-2006-001])                                                                     The metastasis-suppressor protein, nucleoside diphosphate kinase A is increased in the serum of patients with hematological neoplasms ([@b252-bmi-2006-001]).

  OVX1                                                                                                                                                              ✓                    1                     NF                          x                                                                                                                               An ovarian cancer antigen antibody, OVX1 reacted to a majority of ovarian cancer tissues (17 of 20) and did not bind to normal ovarian tissues. ([@b368-bmi-2006-001]).

  OX40                                                                                                                                            ✓                                      1                     yes                         P43489                    7.5E+02    ([@b330-bmi-2006-001]).                                                                    Ox40 helps maintain T cell responses. Solubl OX40 is detectable in serum of subpopulations of healthy donors and patients with autoimmune disease and cancer. Chronic lymphocytic leukemia has been identified as a disease with high frequency of sOX40-positive sera and with the highest mean sOX40 serum concentration ([@b330-bmi-2006-001]).

  p65 oncofetal protein                                                                                                                           ✓                                      1                     NF                          x                         3.7E+04    ([@b227-bmi-2006-001])                                                                     A novel member of the superfamily of genes that encode nuclear receptors for various hydro-phobic ligands such as steroids, vitamin D, retinoic acid, and thyroid hormones, it is increased in 90% of breast cancer patients ([@b227-bmi-2006-001]).

  Pancreatic secretory trypsin inhibitor, TATI                                                                                                    ✓                                      1                     NF                          P00995                    2.1E+04    ([@b222-bmi-2006-001])                                                                     It is secreted from pancreatic acinar cells into pancreatic juice. Its physiologic role has been thought to be the prevention of trypsin-catalyzed premature activation of zymogens within the pancreas and the pancreatic duct. Since it is also found in serum and in various normal and malignant tissues, it may have other roles as well. It is elevated in ovarian cancer ([@b222-bmi-2006-001]).

  Parathyroid hormone-related protein                                                                                                                               ✓                    1                                                 P12272                                                                                                                          A critical regulator of cellular and organ growth, development, migration, differentiation and survival and of epithelial calcium ion transport; parathyroid hormone-related protein is found in the serum of bone metastases ([@b140-bmi-2006-001]), lung cancer ([@b242-bmi-2006-001]) patients and a multiple myeloma patient ([@b162-bmi-2006-001]).

  Pcaf, P300/CBP-associated factor                                                                                             ✓                                                         1                     yes                         Q92831                                                                                                                          Pcaf plays a direct role in transcriptional regulation. The genes for p300, CBP, MOZ and MORF are rearranged in recurrent leukemia-associated chromosomal abnormalities ([@b371-bmi-2006-001]).

  Pepsinogen-1                                                                                                                                    ✓                                      1                     NF                          x                         4.4E+04    ([@b96-bmi-2006-001])                                                                      The precursor of pepsin, one of the main proteolytic enzymes secreted by the gastric mucosa, it is decreased in gastric cancer patients ([@b168-bmi-2006-001]).

  Placental specific tissue protein 12                                                                                                            ✓                                      1                     NF                          x                         5.4E+01    ([@b41-bmi-2006-001])                                                                      A soluble tissue antigen of the placenta, it is increased in lung cancer ([@b41-bmi-2006-001]).

  Plasma retinol-binding protein                                                                                                                  ✓                                      1                     NF                          P02753                    3.2E+07    ([@b183-bmi-2006-001])                                                                     The specific carrier for vitamin A in the blood, it is decreased in leukemia patients ([@b180-bmi-2006-001]).

  Plasminogen (Contains Angiostatin)                                                                                                              ✓                                      1                     NF                          P00747                    1.1E+08    ([@b183-bmi-2006-001])                                                                     The precursor to angiostatin, a potent angiogenesis inhibitor, it is increased in patients with malignant neoplasm of stomach, colon, lung, bladder, breast. renal pelvis, and prostate but decreased in patients with malignant neoplasm of biliary tree, pancrease, cervix uteri, kidney except pelvis, and thyroid ([@b50-bmi-2006-001]).

  Platelet endothelial cell adhesion molecule, PECAM-1                                                                                            ✓                                      1                     yes                         P16284                    6.6E+03    ([@b380-bmi-2006-001])                                                                     Involved in transendothelial migration of leukocytes, angiogenesis, and integrin activation; it is underexpressed in adenocarinomas of the lung ([@b219-bmi-2006-001]) but decreased in patients with recurrent basal cell carcinoma ([@b373-bmi-2006-001]).

  Platelet factor 4                                                                                                                               ✓                                      1                     NF                          P02776                    9.7E+03    ([@b191-bmi-2006-001])                                                                     Promotes coagulation and plays a role in inflammation and wound repair, it is elevated in some cancer patients ([@b191-bmi-2006-001]).

  Platelet-derived growth factor beta polypeptide                                                                                                 ✓                                      1                     yes                         P01127                    3.2E+02    ([@b191-bmi-2006-001])                                                                     A potent mitogen for cells of mesenchymal origin, all gliomas expressed PDGF-B mRNA at higher levels than found in peritumoral and normal nervous tissues ([@b217-bmi-2006-001]).

  Platelet-derived growth factor receptor alpha polypeptide                                                                    ✓                                                         1                     NF                          P16234                                                                                                                          Mediates various growth factors. By Western blot analysis, PDGFR protein expression was detected in 10 of 11 basal cell carcinomas, whereas it was undetectable in the control epidermis ([@b366-bmi-2006-001]).

  Pregnancy zone protein                                                                                                                          ✓                                      1                     NF                          P20742                    8.4E+06    ([@b258-bmi-2006-001])                                                                     A prominent constituent of late-pregnancy sera, it is increased in gynaecological tumors ([@b332-bmi-2006-001]).

  Pregnancy- associated plasma protein-A                                                                                                          ✓                                      1                     NF                          Q13219                    1.0E+03    ([@b262-bmi-2006-001])                                                                     PAPP-A can bind a variety of cytokines and specifically cleave a binding protein for insulin-like growth factors, thereby serving as a modulator of cytokine activity. It is increased in breast cancer ([@b175-bmi-2006-001]).

  Prostate secretory protein PSP94                                                                                                                ✓                                      1                     yes                         P08118                    7.1E+05    ([@b266-bmi-2006-001])                                                                     Inhibits follicle-stimulating-hormone secretion, PSP94 serum measurements, especially of bound and free forms, have potential clinical utility in prostate cancer management ([@b266-bmi-2006-001]).

  P-selectin                                                                                                                                      ✓                                      1                     yes                         P16109                    1.9E+05    ([@b21-bmi-2006-001])                                                                      An adhesion molecule that mediates the interaction of activated endothelial cells or platelets with leukocytes, it is elevated in Hodgkin's and non-Hodgkin's lymphoma ([@b115-bmi-2006-001]).

  PSP94 binding protein                                                                                                                           ✓                                      1                     yes                         x                         7.1E+05    ([@b266-bmi-2006-001])                                                                     It may be involved in hormonal control. It is lower in the serum of prostate cancer patients ([@b266-bmi-2006-001]).

  Pyruvate kinase, isozymes M1/M2                                                                                                                 ✓                                      1                     NF                          P14618                    1.5E+07    ([@b203-bmi-2006-001])                                                                     May play a role in metabolism, an isoenzyme of pyruvate kinase it is overexpressed by some tumor cells including pancreatic tumors ([@b354-bmi-2006-001]).

  Riboflavin carrier protein                                                                                                                      ✓                                      1                     NF                          x                         7.0E+02    ([@b265-bmi-2006-001])                                                                     Riboflavin carrier proteins transports vitamin B2 across placental membranes, a process critical for maintenance of pregnancy. It is 3 to 4-fold higher in breast cancer patients. In addition, there seems to be a good correlation between rising RCP levels and disease progression ([@b152-bmi-2006-001]).

  S100 beta chain                                                                                                                                 ✓                                      1                     NF                          P04271                    9.0E+01    ([@b329-bmi-2006-001])                                                                     S100 binds zinc and calcium. A statistically significant shorter survival was found in patients with high levels ([@b356-bmi-2006-001]). Concentration is for the complex protein.

  Secreted phosphoprotein 1, osteopontin                                                                                                          ✓                                      1                     yes                         P10451                    4.4E+05    ([@b88-bmi-2006-001])                                                                      An extracellular matrix protein of pleiotropic properties including inflammation modulator, it is increased in prostate, colon, breast and lung cancer ([@b88-bmi-2006-001]).

  Serine (or cysteine) proteinase inhibitor clade B, maspin                                                                                       ✓                                      1                     NF                          P05154                    5.3E+06    ([@b187-bmi-2006-001])                                                                     A tumor suppressor decreased in stomach cancer.

  Serine (or cysteine) proteinase inhibitor clade E, PAI-1                                                                                        ✓                                      1                     NF                          P05121                    8.0E+03    ([@b169-bmi-2006-001])                                                                     It inhibits tissue plasminogen activator, urokinase, and protein C. PAI-1 levels were measured in the serum of a small group of head and neck cancer patients and were found to correlate with the degree of tumor hypoxia found in these patients ([@b169-bmi-2006-001]).

  Serum amyloid alpha-1                                                                                                                           ✓                                      1                     yes                         P02735                    3.6E+07    ([@b94-bmi-2006-001])                                                                      The proteolytic cleavage product of an acute phase reactant, it is differentially expressed in renal cancer ([@b337-bmi-2006-001]).

  Serum paraoxonase/ arylesterase 1                                                                                                               ✓                                      1                     NF                          P27169                    5.9E+07    ([@b176-bmi-2006-001])                                                                     Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. It is decreased in gastric ([@b7-bmi-2006-001]) and pancreatic ([@b6-bmi-2006-001]) cancer patients.

  Small inducible cytokine A14 CCL14                                                                                                              ✓                                      1                     yes                         Q16627                    8.5E+03    ([@b322-bmi-2006-001])                                                                     CCL14 enhances proliferation of CD34 positive stem cells, it is differentially expressed in lobular versus ductal tumors ([@b170-bmi-2006-001]).

  Small inducible cytokine A18(CCL18), MIP-4                                                                                                      ✓                                      1                     NF                          P55774                    3.1E+04    ([@b322-bmi-2006-001])                                                                     An immune modulator that governs antigen presenting dendritic cells and immature T cells.

  Small inducible cytokine A2(CCL2)                                                                                                               ✓                                      1                     yes                         P13500                    1.8E+02    ([@b188-bmi-2006-001])                                                                     CCL2 is a monocyte, chemotactic and activating factor increased in some breast cancer ([@b188-bmi-2006-001]).

  Small inducible cytokine A3(CCL3), Macrophage inflammatory protein 1-alpha                                                                      ✓                                      1                     yes                         P10147                    3.7E+01    ([@b106-bmi-2006-001])                                                                     MIP-1 alpha is an immunoregulatory and inflammatory molecule increased in myeloma ([@b333-bmi-2006-001]).

  Small inducible cytokine B5(CXCL5)                                                                                                              ✓                                      1                     yes                         P42830                    4.0E+02    ([@b79-bmi-2006-001])                                                                      CXCL5 is involved in neutrophil activation. Its gene expression is suppressed in malignant nasopharyngeal epithelial cells ([@b93-bmi-2006-001]).

  Squamous cell carcinoma antigen 1                                                                                                               ✓                                      1                     NF                          P29508                    4.2E+03    ([@b46-bmi-2006-001])                                                                      A member of the ovalbumin family of serine proteinase inhibitors, it serves as a serologic marker for advanced squamous cell carcinomas of the uterine cervix, lung, esophagus, head and neck and vulva. Recent molecular studies show that SCCA is transcribed by two nearly identical genes (SCCA1 and SCCA2) that encode for members of the high molecular weight serine proteinase inhibitor (serpin) family ([@b46-bmi-2006-001]).

  Squamous cell carcinoma antigen 2                                                                                                               ✓                                      1                     NF                          P48594                    2.0E+03    ([@b295-bmi-2006-001])                                                                     SCCA2 may act as a protease inhibitor to modulate the host immune response against tumor cells. It is significantly elevated in cervical cancer ([@b27-bmi-2006-001]).

  Survivin                                                                                                                                        ✓                                      1                     yes                         O15392                    1.2E+02    ([@b36-bmi-2006-001])                                                                      Survivin is an apoptosis inhibitor upregulated in adult T cell leukemia and acute leukemia but downregulated in chronic lymphocytic leukemia ([@b323-bmi-2006-001]).

  Syndecan-1                                                                                                                                      ✓                                      1                     NF                          P18827                    4.0E+04    ([@b182-bmi-2006-001])                                                                     A cell surface proteoglycan, it is an integral membrane protein acting as a receptor for the extracellular matrix. It is expressed in most multiple myeloma patients ([@b182-bmi-2006-001]).

  synuclein-gamma                                                                                                              ✓                                                         1                     NF                          O7607                                                                                                                           Synuclein-gamma plays a role in neurofilament network integrity. It is found in sera from 21 of 56 pancreatic patients ([@b195-bmi-2006-001]).

  TEK tyrosine kinase endothelial, Tie-2                                                                                                          ✓                                      1                     yes                         Q02763                    8.5E+03    ([@b56-bmi-2006-001])                                                                      Tie-2 is involved in angiogenesis, vasculogenesis and hematopoiesis. Increased in breast and prostate cancer ([@b45-bmi-2006-001]).

  Tenascin                                                                                                                                        ✓                                      1                     yes                         P24821                    1.0E+06    ([@b292-bmi-2006-001])                                                                     An extracellular matrix protein with a spatially and temporally restricted tissue distribution, it is elevated in cancer patients especially patients with high C-reactive protein levels ([@b291-bmi-2006-001]).

  Tetranectin                                                                                                                                     ✓                                      1                     NF                          P05452                    8.2E+06    ([@b130-bmi-2006-001])                                                                     A plasma protein that has a specific binding affinity for sulfated polysaccharides and the kringle 4 of plasminogen, it is an independent prognostic factor in ovarian cancer ([@b31-bmi-2006-001]).

  TGF-beta receptor type III                                                                                                   ✓                                                         1                     NF                          Q03167                                                                                                                          A TGF-beta binding protein, it may retain TGF-beta for the signaling receptors. It is differentially expressed in ovarian cancer ([@b233-bmi-2006-001]).

  Thioredoxin reductase 1, cytoplasmic                                                                                                            ✓                                      1                     NF                          Q16881                    1.8E+04    ([@b311-bmi-2006-001])                                                                     A redox-active protein that participates in multiple cellular events, including growth promotion, apoptosis, and cytoprotection; it is over expressed leukemia dna melanoma ([@b311-bmi-2006-001]).

  Thrombopoietin                                                                                                                                  ✓                                      1                     yes                         P40225                    7.8E+04    ([@b120-bmi-2006-001])                                                                     Thrombopoietin may indirectly enhance erythropoiesis. It is increased in acute myeloblastic leukemia and myelodysplastic syndrome ([@b135-bmi-2006-001]).

  Thrombospondin 1                                                                                                                                ✓                                      1                     NF                          P07996                    2.1E+05    ([@b114-bmi-2006-001])                                                                     Thrombospondin I is a multimodular secreted protein that associates with the extracellular matrix and possesses a variety of biologic functions, including a potent angiogenic activity. Staining for thrombospondin is positive in hepatocellular carcinoma and a prognostic marker of poor survival ([@b259-bmi-2006-001]).

  Thymidine kinase, cytosolic                                                                                                                     ✓                                      1                     yes                         P04183                    1.0E+01    ([@b72-bmi-2006-001])                                                                      Thymidine kinase is a DNA replication enzyme that can provide prognostic information on progression-free survival in leukemia patients ([@b110-bmi-2006-001]).

  Tissue inhibitor of metalloproteinase 1                                                                                                         ✓                                      1                     yes                         P01033                    9.5E+04    ([@b244-bmi-2006-001])                                                                     A modulator of interstitial collagenase as well as a number of connective tissue metalloendoproteases, TIMPs can form complexes with extracellular matrix metalloproteinases (such as collagenases) and irreversibly inactivate them. The plasma concentration of TIMP-1 in colorectal carcinoma correlates with both invasion and metastasis ([@b379-bmi-2006-001]).

  Tissue inhibitor of metalloproteinase 2                                                                                                         ✓                                      1                     yes                         P16035                    3.4E+04    ([@b245-bmi-2006-001])                                                                     TIMPs can form complexes with extracellular matrix metalloproteinases (such as collagenases) and irreversibly inactivate them. TIMP-2 is reduced in prostate cancer ([@b196-bmi-2006-001]).

  Tissue-type plasminogen activator, tPA                                                                                                          ✓                                      1                     yes                         P00750                    7.3E+03    ([@b99-bmi-2006-001])                                                                      Tissue plasminogen activator is a serine protease that activates the proenzyme plasminogen to plasmin, which in turn is responsible for fibrinolytic activity. tPA is decreased in gastric neoplastic tissues ([@b289-bmi-2006-001]).

  Transferrin receptor (p90 CD71)                                                                                                                 ✓                                      1                     NF                          P02786                    5.2E+06    ([@b200-bmi-2006-001])                                                                     TFRC is a ubiquitously distributed antigen on the cell surface of actively growing human cell. It is upregulated on neuroendocrine carcinomas of the pancrease([@b281-bmi-2006-001]) and a sensitive serum measurement of erythropoiesis and iron deficiency ([@b303-bmi-2006-001]).

  Transforming growth factor alpha                                                                                                                ✓                                      1                     yes                         P01135                    1.5E+01    ([@b54-bmi-2006-001])                                                                      TGF-alpha, a potent mitogenic polypeptide, is present in most gallbladder carcinoma tissue ([@b189-bmi-2006-001]) and the plasma of ovarian cancer patients ([@b54-bmi-2006-001]).

  Transforming growth factor beta 1                                                                                                               ✓                                      1                     yes                         P01137                    1.4E+04    ([@b304-bmi-2006-001]) ([@b299-bmi-2006-001]) ([@b82-bmi-2006-001])                        A transforming growth factor, regulated at the protein level with both inhibitory and stimulatory activities. TGF-beta 1 levels are increased in patients with prostate lymph node and bone metastases ([@b299-bmi-2006-001]), invasive bladder cancer ([@b82-bmi-2006-001]) and cervical cancer ([@b77-bmi-2006-001]).

  transthyretin                                                                                                                                   ✓                                      1                     NF                          P02766                    3.0E+08    ([@b353-bmi-2006-001])                                                                     A thyroid hormone binding protein decreased in ovarian cancer patients ([@b382-bmi-2006-001]).

  Tropomyosin 1 alpha chain (Alpha-tropomyosin)                                                                                                   ✓                                      1                     NF                          P09493                    2.0E+03    ([@b64-bmi-2006-001])                                                                      Tropomyosins are ubiquitous proteins of 35 to 45 kD associated with the actin filaments of myofibrils and stress fibers. It is decreased in pancreatic cancer ([@b9-bmi-2006-001]).

  Tumor necrosis factor (ligand) superfamily member 5, CD154                                                                                      ✓                                      1                     NF                          P29965                    1.3E+02    ([@b277-bmi-2006-001])                                                                     CD154 is a B cell stimulator increased in lung cancer ([@b277-bmi-2006-001]).

  Tumor necrosis factor (ligand) superfamily member 6, Fas ligand                                                                                 ✓                                      1                     yes                         P48023                    2.5E+04    ([@b283-bmi-2006-001])                                                                     An apoptosis mediator increased in leukemia, lymphoma ([@b328-bmi-2006-001]), and gastric carcinoma patients ([@b348-bmi-2006-001]).

  Tumor necrosis factor ligand superfamily member 13B, TALL-1                                                                                     ✓                                      1                     yes                         Q9Y275                    2.5E+03    ([@b234-bmi-2006-001])                                                                     It can induce activation, proliferation, differentiation, or death in B cells. It is elevated in the serum of patients with systemic autoimmune diseases and in patients with B-lymphoid malignancies ([@b206-bmi-2006-001]).

  Tumor necrosis factor receptor superfamily member 11B, osteoprotegerin                                                                          ✓                                      1                     yes                         O00300                    3.5E+01    ([@b182-bmi-2006-001])                                                                     A secreted glycoprotein that regulates bone resorption, osteoprotegerin is increased in patients with bone metastases ([@b148-bmi-2006-001]) and multiple myeloma ([@b182-bmi-2006-001]).

  Tumor necrosis factor receptor superfamily member 1A p60 TNF-RI p55 CD120a, TNFR1                                                               ✓                                      1                     yes                         P19438                    9.1E+02    ([@b14-bmi-2006-001])                                                                      An immune modulator receptor elevated in patients with malignant astrocytomas of the brain ([@b14-bmi-2006-001]).

  Tumor necrosis factor receptor superfamily member 1B, TNFR2                                                                                     ✓                                      1                     yes                         P20333                    4.0E+03    ([@b349-bmi-2006-001])                                                                     The main TNF receptor found on circulating T cells, it is the major mediator of autoregulatory apoptosis in CD8+ cells. TNFR2 may act with TNFR1 to kill nonlymphoid cells. It is elevated in patients with malignant astrocytomas of the brain ([@b14-bmi-2006-001]).

  Urokinase plasminogen activator surface receptor, U-PAR                                                                                         ✓                                      1                     yes                         Q03405                    3.0E+03    ([@b273-bmi-2006-001])                                                                     The urokinase-type plasminogen activator receptor is a key molecule in the regulation of cell-surface plasminogen activation. It is increased in colorectal cancer and associated with poor prognosis in patients with metatatic breast cancer ([@b31-bmi-2006-001]).

  Vascular cell adhesion molecule 1                                                                                                               ✓                                      1                     yes                         P19320                    4.8E+05    ([@b44-bmi-2006-001])                                                                      VCAM-1 mediates the adhesion of monocytes and lymphocytes to cytokine-activated endothelium. It is correlated with microvessel density in early breast cancer tumors and increased in women with lymph node-positive and high-grade breast tumors ([@b43-bmi-2006-001]).

  Vascular endothelial growth factor receptor 2                                                                                                   ✓                                      1                     yes                         P35968                    1.5E+04    ([@b275-bmi-2006-001])                                                                     The VEGF-flk-1 system takes part in tumor angiogenesis, proliferation, and apoptosis in colon liver metastases ([@b53-bmi-2006-001]).

  Vasoactive intestinal peptide                                                                                                                                     ✓                    1                     NF                          P01282                                                                                                                          VIP causes vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, increases glycogenolysis and relaxes the smooth muscle of trachea, stomach and gall bladder. It is increased two fold in adenocarcinoma patients ([@b61-bmi-2006-001]).

  VEGF(165)b                                                                                                                                      ✓                                      1                     NF                          x                         4.2E+01    ([@b362-bmi-2006-001])                                                                     Possesses anti-angiogenic action. This isoform was present in 17 of 18 normal kidney samples but only 4 of 18 cases from matched malignant tissue ([@b29-bmi-2006-001]).

  Vitamin K dependent protein C                                                                                                                   ✓                                      1                     NF                          P04070                    3.7E+06    ([@b149-bmi-2006-001])                                                                     A vitamin K-dependent serine protease that regulates blood coagulation, it is differentially expressed in ovarian cancer ([@b233-bmi-2006-001]).

  Vitronectin                                                                                                                                     ✓                                      1                     NF                          P04004                    3.4E+05    ([@b129-bmi-2006-001])                                                                     Vitronectin promotes attachment and spreading of animal cells in vitro, it inhibits cytolysis by the complement C5b-9 complex, and modulates antithrombin III-thrombin action in blood coagulation. It is upregulated in colorectal carcinoma ([@b338-bmi-2006-001]).

  X box binding protein-1                                                                                                      ✓                                                         1                     NF                          P17861                                                                                                                          A transcription factor essential for hepatocyte growth, the differentiation of plasma cells, immunoglobulin secretion, and the unfolded protein response. It is increased in identical twins with multiple myeloma([@b238-bmi-2006-001]) hXBP-1 mRNA expression was increased in primary breast cancers but hardly detectable in non-cancerous breast tissue ([@b91-bmi-2006-001]).
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